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ABSTRACT 
DIFFUSION OF THE EGFR ASSAY: THE UNDERUTILIZATION AND THE 
URBAN/RURAL DIVIDE 
June 2012 
Julie A. Lynch, B.S., University of Massachusetts Boston 
PhD., University of Massachusetts Boston 
 
Directed by Professor Jerry Cromwell 
Purpose: The EGFR assay is a molecular diagnostic test which identifies a 
targetable mutation in lung tumors. Guidelines call for EGFR testing for non-small cell 
lung cancer patients to direct first line treatment. I explored institutional and regional 
factors predicting the likelihood acute care hospitals ordered the assay. Methods: This 
was a retrospective study which analyzed US acute care hospitals (n=4780). I linked 
proprietary industry data for orders of the EGFR assay to public datasets that provided 
hospital and regional characteristics. I conducted logistic regression to identify significant 
characteristics that predict likelihood a hospital ordered the assay.  Results: Of acute care 
hospitals in the US, 12% (n=592) ordered the EGFR assay. In 49 counties with an NCI 
designated cancer center (NCI CC), 19% of hospitals ordered the assay. Hospital and 
regional characteristics had the hypothesized effect on likelihood a hospital would order 
the EGFR assay. Significant institutional predictors of ordering the assay included: 
Participation in an NCI clinical research cooperative group (odds ratio [OR], 2.06, 95% 
CI 1.66 to 2.55), Cardiothoracic Surgery (OR, 1.90; 95% CI, 1.52 to 2.37), PET Scan 
services (OR, 1.44, CI, 1.07 to 1.94), and affiliation with academic medical center (OR, 
 v 
 
1.48; 95% CI, 1.20 to 1.83). Inpatient chemotherapy services were not statistically 
significant once all other institutional characteristics were stepped in. Significant regional 
predictors included: metropolitan county (OR, 2.08; 95% CI, 1.48 to 2.91), education 
above the mean (OR, 1.46; 95% CI, 1.09 to 1.96), and income above the mean (OR, 1.46; 
95% CI, 1.09 to 1.96). Negative predictors were distance from an NCI CC (OR, .996, 
95% CI, .995 to .998), a 34% decrease in likelihood for every 100 miles further from an 
NCI CC. 
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CHAPTER 1 
Purpose 
The purpose of this thesis was to conduct an analysis of the diffusion of the epidermal 
growth factor receptor (EGFR) assay, a molecular diagnostic test designed to identify a 
specific somatic mutation in lung tumor tissue.  The EGFR assay is an important 
innovation in the diagnosis and treatment of patients with non small cell lung cancer 
(NSCLC). Early identification of EGFR mutations in patients’ lung tumors can improve 
the treatment and outcome for many such patients. The primary objectives of this analysis 
was to: 1) Identify institutional and regional factors that contributed to the adoption and 
utilization of the EGFR assay; 2) Elucidate structural factors that may contribute to 
differences in access to this technology; 3) Examine potential implications that 
differential rates of adoption have for poor patients living in rural counties; 4) Consider 
the role of nursing in administration, education, research, policy, and as patient advocate, 
to improve equity in access and utilization to advanced molecular diagnostic tests and to 
ensure implementation of evidence based clinical practice guidelines.  
This was a retrospective, observational study using secondary data analysis 
research methods. The research was conducted on a national proprietary data set provided 
by Genzyme Genetics which identified institutions that ordered the EGFR assay for their 
patients in 2010. The proprietary dataset was merged with national, publicly available 
data sets including: Census Bureau Population Data (Census), National Institute of 
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Standards and Technology (NIST) county identification and location data, The National 
Program of Cancer Registries and Centers for Disease Control and Prevention 
(NPCR/CDC) State Cancer Profiles data, the 2009 Center for Medicare and Medicaid 
Services (CMS) and National Cancer Institute (NCI) Provider of Services institutional 
characteristics data (CMS/NCI POS). 
The conceptual model that guided this research was based on four distinct bodies of 
literature: 
(1) Clinical processes and guidelines for diagnosis and treatment of non small cell 
lung cancer 
(2) Lung cancer disparities research 
(3) Clinical trials of EGFR tyrosine kinase inhibitors (TKIs) and the EGFR assay 
(4) Diffusion of innovation of healthcare services and technologies research 
This literature helped generate the overall hypotheses that NCI designated cancer centers 
(CCs) serve as hubs from which diffusion of the EGFR assay emanates. The conceptual 
model was a two stage model. Stage one was a regional analysis with two dependent 
variables. The first dependent variable was the likelihood a county has an AMC that 
obtains designation from the NCI as a cancer center. The second dependent variable was 
the county utilization rate of the EGFR assay. Stage two of the conceptual model 
analyzed the likelihood individual institutions ordered at least one EGFR during the year 
2010. The conceptual model proposes and tests two different measures of diffusion.  One 
measure of diffusion was the county rate of utilization of the EGFR assay. It measured 
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the number of tests ordered within the county relative to the number of lung cancer cases 
in that county for which guidelines recommend testing. Throughout the thesis, this 
regional measure of diffusion will be called the utilization rate. The second measure of 
diffusion was the adoption of the EGFR assay by acute care hospitals within counties. In 
this paper, a hospital is considered to have adopted the EGFR assay if it ordered just one 
EGFR assay for a patient.  
One of the limitations of this study was the lack of comprehensive information 
about the number of EGFR assays conducted by sixty clinical care NCI CCs. There were 
orders from twenty seven NCI CCs. However, many of these NCI CCs also conduct the 
EGFR assay independently.  Therefore, all orders from NCI CCs were removed from the 
database. Given that limitation, the overall research hypothesis was utilization rate of the 
EGFR assay will be highest in counties in close proximity to NCI CCs, with the lack of 
information about NCI CC orders artificially suppressing the utilization rate within NCI 
CC counties, as well as for the entire United States (US).   
The adoption of the EGFR assay, as measured by an institution ordering the 
assay,  should be greatest among institutions that are either in close proximity to NCI 
CCs or that interact with NCI CCs through participation in cooperative clinical research 
groups. These institutions are also more likely to be affiliated with AMCs, early adopters 
of technology with the capabilities and equipment to offer advanced cancer care services, 
and located in metropolitan counties where the patient population has high income, 
education, and socioeconomic status. Institutions that are located in counties distant from 
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NCI CCs or are in rural counties that lack an NCI CC should be less likely to adopt the 
EGFR assay.  
It was hoped that this analysis would shed light upon whether regional differences 
in access to molecular cancer diagnostics was a significant factor in the widening gap in 
quality and outcomes of healthcare services. Findings of this study will be used to inform 
a follow-up study which will examine patient level variables associated with access, 
adoption, and utilization of this healthcare innovation to determine whether barriers 
impact specific ethnic or racial groups. 
Aims 
The specific aims of this proposed study were: 
(1) Create a dataset that links proprietary data provided by Genzyme Genetics, which 
identified institutions that ordered the EGFR assay for their patients in 2010, to 
several public use data sets.  To achieve this aim, the following processes were 
conducted: 
a. Aggregated the individual orders for the EGFR assay to the institution and 
county level. 
b. Matched the institutional name listed in the Genzyme Genetics dataset to 
the name in the CMS/NCI POS datasets.  
c. Obtained CMS Oscar number for each institution that uniquely identified 
it. 
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d. Used the institution’s zip code and county code to link and import 
proprietary and public datasets, which provide information about: 
i. Characteristics of the acute care hospitals operating within the 
county. 
(i) Annual lung cancer incidence and average annual number of lung 
cancer cases.  
(ii)  Population socioeconomic and demographic data of the county in 
which these hospitals are located.  
(iii)  Locational data that allows for geocoding and mapping of the 
institutions ordering the EGFR assay. 
(2) Conducted exploratory analysis of the data to identify characteristics of the 
institutions and regions ordering the EGFR assays. 
(3) Conduct descriptive and inferential statistical analysis of data. 
a. Use descriptive statistics to summarize the independent variables that are 
associated with diffusion of the EGFR assay innovation. 
b. Identify factors within specific counties that lead to healthcare institutions 
receiving the NCI designation. 
c. Use logistic regression to analyze the odds ratio that a specific institution 
or county will have adopted the EGFR assay.  
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d. Use multiple regression analysis to calculate the strength of the causal 
relationship between the independent institutional and regional variables 
and EGFR assay utilization rate. 
(4) Conclusions and implications that inform policy 
Conceptual Modeling 
The conceptual model that guides this research is based on four distinct bodies of 
literature: 
(1) Clinical processes and guidelines for diagnosis and treatment of non small cell 
lung cancer 
(2) Lung cancer disparities research 
(3) Clinical trials of EGFR TKIs and the EGFR assay 
(4) Diffusion of innovation of healthcare services and technologies research 
A thorough review of the literature in each of these areas is conducted in Chapter 2. The 
discussion in this chapter is limited to a summary of the significant findings that informed 
the conceptual model and causal hypotheses.   
Clinical processes and guidelines for diagnosis and treatment of NSCLC 
Lung cancer treatment options are determined by stage of disease, performance 
status, tumor histology and presence of oncogenic mutations.  NSCLC accounts for 85% 
of all lung cancers and adenocarcinomas represents 40% of NSCLC cases (Ettinger et al., 
2010). Lung cancer is initially a silent disease which does not cause obvious signs or 
symptoms.  In a small percentage of patients, early stage lung cancer may be discovered 
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accidentally through a chest x-ray related to another medical procedure or due to a 
coincidental, co-occurring respiratory infection.  However, the majority of patients do not 
experience signs or symptoms of the disease until it has spread beyond the lungs and they 
are in the late stages of the disease process. For approximately 100,000 patients who have 
lung cancer, they will first experience vague respiratory symptoms which they, as well as 
their primary care provider, may suspect is either a viral or bacterial upper respiratory 
infection. Often, these symptoms are simply tolerated or treated with over the counter 
cough expectorants or suppressants. If symptoms persist, become worse, if a patient is 
coughing up blood (experiencing hemoptysis), or is in pain, these symptoms will 
encourage them to visit a hospital emergency room or their primary care physician.  In 
both cases, the patient will likely have a chest x-ray. If a patient has respiratory 
symptoms and a suspicious mass is visible on a chest x-ray, clinical practice guidelines 
recommend the patient be referred to further imaging studies such as computerized 
tomography (CT) scan, magnetic resonance imaging (MRI), or positron emission 
tomography (PET) (Alberg, Ford, Samet, & American College of Chest Physicians, 
2007). However, depending upon patient, institutional, and regional factors, the patient 
may or may not benefit from clinical practice guidelines. Patient factors that limit access 
to certain procedures include clinical symptoms, comorbid conditions, and 
sociodemographic factors. Institutional factors that may limit access are capabilities of 
the hospital or site of care and knowledge/expertise of providers. Regional factors that 
may limit access are physician practice patterns, availability and concentration of 
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healthcare providers and technologies, and population characteristics.  All these are 
discussed in detail in Chapter 2 in the section of disparities in lung cancer treatment and 
outcomes.  
Many patients die from lung cancer having only received a chest x-ray or an 
imaging study. Yet, conclusive diagnosis of lung cancer requires tumor tissue analysis. 
Health services researchers are discovering that clinical practice guidelines, like the 
EGFR assay, are a form of innovation that have differential rates of diffusion and which 
impact whether patients benefit from these guidelines. Assuming the patient benefits 
from clinical practice guidelines, when there is a suspicious finding on an imaging study, 
the patient should then be referred to an invasive procedure to extract tumor tissue. It is 
important to emphasize that conclusive diagnosis of NSCLC requires a pathologist to 
examine lung tissue under a microscope. Therefore, in theory, of the 222,000 patients 
who were diagnosed with lung cancer in the U.S. in 2010, approximately 68% (those 
with histology of non squamous cell NSCLC) should potentially have had access to the 
EGFR assay. However, the reality is that at any point in the clinical decision making 
process, large segments of the patient population are either denied access due to clinical 
reasons, institutional, or regional characteristics. Chapter 4 provides an analysis of the 
expected patient population that would have access to and utilize the EGFR assay. 
Stage drives prognosis, treatment, and outcomes for patients with lung cancer. 
Although a detailed discussion of the treatment options in each stage are beyond the 
scope of this paper, it is important to understand the potential number of patients for 
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which tumor tissue extraction was realistically advisable and feasible. Generally, patients 
are eligible for surgical resection if they are diagnosed prior to stage IIIB when the cancer 
has spread to distant lung tissue or lymph nodes.  Therefore, for approximately 100,000 
patients in 2010 (those with Stage I to IIIA), surgical resection of the cancer may have 
been possible. Yet regardless of whether a patient is eligible for surgery, clinical practice 
guidelines recommend a tissue biopsy.  
Depending upon location and accessibility of the suspicious mass, tissue biopsy 
could be performed by either bronchoscopy with transbronchial needle aspiration 
(TBNA), mediastinoscopy, endobronchial ultrasound-needle aspiration (EBUS-NA), 
endoscopic ultrasound-needle aspiration (EUS-NA), or transthoracic needle aspiration 
(TTNA) (Alberg et al., 2007). These guidelines recommend which procedure is best 
given clinical presentation, location of the tumor, and patient preferences. If a physician 
does not refer a patient to a procedure to conclusively diagnose lung cancer, that 
physician has impeded access to biopsy, surgery and the EGFR assay technology. In a 
few rare cases, the lack of referral may be clinically warranted due to debilitating 
coexisting medical conditions.  If that physician refers the patient to surgery but the 
copayment prevents the patient from undergoing the procedure, health disparity 
researchers contend that socioeconomic factors have impeded access to both the surgery 
as well as the EGFR assay. If, on the other hand, the physician makes the referral and 
there are no financial or other structural barriers that impede access, yet the patient 
chooses non-treatment, then the patient had access but lacked utilization. The importance 
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of distinguishing between access and utilization may be unique to diffusion of healthcare 
services.  It is particularly important to distinguish between these issues to elucidate 
causes of lung cancer disparities.  
Disparities in lung cancer treatment and EGFR TKI clinical trials 
Two decades of lung cancer disparities research illustrate racial, regional, and 
socioeconomic differences in access and utilization of bronchoscopy, surgical 
procedures, radiation therapy, chemotherapy clinical trials, and standard care 
(Greenwald, Polissar, Borgatta, McCorkle, & Goodman, 1998, Bach, Cramer, Warren, & 
Begg, 1999, Lathan, Neville, & Earle, 2006, Newman et al., 2004, Gross, Smith, Wolf, & 
Andersen, 2008). These finding were further reinforced by a systematic review conducted 
by the author of more than thirty-seven multicenter EGFR TKI and biomarker clinical 
trials that took place from 2001 until 2010. This review revealed that, of nearly 10,000 
patients who participated in phase II and phase III EGFR TKI clinical trials, only 247 
(3%) of patients who self identify as Black were enrolled in these studies.  Similarly, 
there were only 219 (2%) patients who self identify as Hispanic. Institutions and patient 
groups that are most likely to utilize the EGFR assay are those who participated in and 
benefited from initial research studies to test the efficacy of this treatment relative to the 
standard of care.  There is some overlap between findings in the EGFR TKI systematic 
review and the lung cancer disparities research. Both demonstrate a lack of participation 
among minority patient groups in standard care and clinical trial research.  
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Recent research by the Dartmouth Atlas Project indicate that geographic variation 
in the use of evidence-based medicine (EBM) is often even larger than racial disparities 
in care (Welch, Sharp, Gottlieb, Skinner, & Wennberg, 2011, Onega, Duell, Shi, 
Demidenko, & Goodman, 2010). Elucidating whether differences in access, utilization, 
and outcomes are caused by patient, providers, or structural factors is difficult. However, 
understanding these differences is fundamental to developing conclusive, clinically 
informed hypotheses about diffusion of the EGFR assay. Conclusions drawn from this 
research suggest that while socioeconomic and demographic variables such as race, 
income, and education, might be considered exogenous variables in empirical non-health 
services related research, these results call for their inclusion as endogenous variables in 
this causal model.   
Diffusion of innovation  
Roger’s diffusion of innovation framework (1962) proposed three categories of 
variables that influence adoption and dissemination of new technologies: Characteristics 
of the social network; Attributes of the innovation; Aspects of the decision process 
(Rogers, 1962). Applying this framework to the EGFR assay informed the conceptual 
model in the following manner: 
Characteristics of the social network 
According to Rogers, healthcare providers’ decision to use new products or 
change their practice patterns is strongly influenced by aspects of the professional social 
network in which they operate. He characterized the social network by existence of 
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opinion leaders, connectedness the members of the social network, their need for 
communication and their tolerance of risk. Analyzed in the context of adoption of the 
EGFR assay: 
(1) Opinion leaders - Both the institution and healthcare providers that operate 
within the NCI CC serve as key opinion leaders with respect to the process of 
diffusion of the EGFR assay. Other institutions and healthcare providers that 
are within NCI CC network/communication channels are likely to be exposed 
to information about new technologies which are being developed and 
implemented in patient care at NCI CCs.  Therefore these institutions adopt 
this technology sooner than healthcare providers operating at institutions 
distant to the NCI CC. 
(2) Connectedness - The greater the number of NCI CCs and other hospitals 
affiliated with AMCs, the more network connectedness these oncologists have 
with oncologists operating in smaller community hospitals nearby. 
(3) Members need for communication – Hospitals with an academic affiliation 
have a large number of young, transient medical staff and fellows working in 
their institutions who are linked by weaker social ties. When members of a 
group are transient, as occurs in AMCs with short term presence of residents, 
fellow, visiting faculty and physicians, there is a need to share information 
more frequently between members, which positively influences diffusion.   
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(4) Tolerance for risk - Healthcare providers working at hospitals with an 
academic affiliation and NCI CCs may be more tolerant of risk relative to 
their counterparts operating at small community hospitals that are distant from 
a population density. Tolerance of risk is influenced by age of residents and 
fellows, linkage to key opinion leaders, and knowledge about the science of 
the EGFR assay.  Attendings and fellows operating within larger AMCs may 
be more insulated or protected from the risk of lack of financial 
reimbursement than permanent MDs operating within smaller community 
hospitals.  The perception of lack of reimbursement may contribute to 
providers at community hospitals being more risk averse to adopting new 
technologies due to concern or lack of knowledge about reimbursement. 
Attributes of the innovation 
The ease and speed with which an innovation is taken up in the market is 
influenced by characteristics of the innovation and features of the product or service used 
in conjunction with, or in lieu of, the innovation.  Rogers described these attributes as: 
relative advantage, compatibility, complexity, trialability, and observability (Rogers, 
1962). 
(1) Relative Advantage - When oncologists order the EGFR assay for a patient 
and an EGFR mutation is detected, the patient is often treated with an EGFR 
TKI in a first line setting. The oncologist then observes the benefit of knowing 
the mutational status.  If the assay is not utilized, the patient may still receive 
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an EGFR TKI in the second or third line setting. Experience with an EGFR 
TKI has a positive influence on the diffusion of the EGFR assay.  Oncologists 
who have not experienced (either directly or through their social network) the 
relative advantage of the EGFR assay to guide treatment, may perceive the 
relative advantage of the EGFR assay as less than their colleagues who have 
had experience with the assay. Therefore, both institutional and regional 
characteristics of the social network in which oncologists operate impact their 
perception of relative advantage of the EGFR assay. Oncologists who operate 
within a social network, in which opinion leaders have participated in the 
EGFR TKI clinical trials, will have directly or indirectly been exposed to the 
relative advantage of the EGFR assay. Experience with the EGFR assay and 
experience prescribing EGFR TKIs will increase the perception of the relative 
advantage and will increase adoption.   
(2) Compatibility - Genetic analysis of tumor tissue began entering oncology 
practice in the mid 1990s with the treatment of Her2 positive breast cancers.  
For oncologists who operate within institutions that have the capability to 
provide advanced cancer care, adoption of the EGFR assay to identify the 
molecular biology of lung tumors will be consistent and compatible with other 
types of cancer care. One marker of an institution’s capability to provide 
advanced cancer care may be utilization of other established cancer care 
technologies such as positron emission tomography (PET) scans technology. 
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(3) Complexity or simplicity - Genetic analysis of tumor tissue is a complex 
technology.  However, the process of ordering the laboratory test from 
Genzyme Genetics is simple and routine.  Institutions that participate in 
clinical research, offer advanced cancer care, and are classified as AMCs 
routinely send tumor tissue to outside labs for analysis.  These institutions will 
perceive the EGFR assay as having less complexity. This will lead to faster 
adoption and diffusion of the technology within those institutions. 
(4) Trialability - Institutional participation in clinical research provides MDs with 
the opportunity to trial the technology.  Institutions that participate in an NCI 
clinical research cooperative group, or are identified as having an affiliation 
with an academic center are more likely to have trialed the EGFR assay and 
therefore adopt the technology. 
(5) Observability - Although observability is not applicable to the EGFR assay, 
one might substitute whether the technology is easily identifiable to patient 
and physician groups.  One barrier to diffusion of the EGFR assay is that lung 
cancer patients tend to be older and diagnosed at later stages.  Therefore, the 
number of patients that can communicate about the technology to create 
visibility for the technology is limited compared to an assay used in diagnosis 
of cancers which are more chronic and less terminal, such as breast cancer.  
Although this attribute of the innovation certainly influences diffusion, there 
is no variable in our data that would measure observability. 
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Characteristics of the decision 
Rogers also proposed that aspects of the decision to adopt innovation influenced 
diffusion. If the decision is optional, made by an individual rather than as a collective or 
in response to some authority or policy dictating it’s use, then adoption is less likely to 
occur. These are discussed in the context of the characteristics of ordering the EGFR 
assay: 
(1) Optional innovation decision - The decision to order the EGFR assay for a 
specific patient remains at the discretion of the individual physician, often an 
oncologist, surgeon, or pathologist. 
(2) Collective innovation decision – Beginning in April 2010, the National 
Comprehensive Cancer Network (NCCN) and the American Society of 
Clinical Oncology (ASCO) called for use of the EGFR assay for diagnosis and 
treatment of specific lung cancer patients.  Although clinical practice 
guidelines seek to improve translation of new technology into practice, the 
decision to follow the guidelines remains in the purview of the individual 
physician. 
(3) Authority innovation decision - In countries with publicly funded health 
service systems, such as the United Kingdom, a government agency may issue 
guidelines for care or reimbursement that may essentially mimic an authority 
innovation-decision process.  In the United States (US), such guidelines more 
often restrict the diffusion of a new medical technology rather than promote it.  
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Currently, Medicare pays for reimbursement of the EGFR assay. However, 
Medicare policy does not ensure the physician has knowledge of that 
coverage. While reimbursement is not a significant barrier, particularly 
because the majority of patients diagnosed with lung cancer are over age sixty 
five and qualify for Medicare. Reimbursement did not result in the automatic 
adoption which might be observed in an authority-innovation decision 
process. 
While the process of diffusion of innovation has been well researched in other markets, 
particularly consumer markets, only recently has it been applied to the healthcare services 
market.  Few health disparity researchers applied the framework to analyze differences in 
access, utilization, and outcomes in healthcare. Roger’s framework (1962) was a useful 
tool for articulating and categorizing variables within a causal model of diffusion. Yet, 
there are some important limitations worth noting. Rogers’s model does not adequately 
address the barriers to diffusion that a complex regulatory and reimbursement 
environment can impose.  Reimbursement of the EGFR assay is likely restricted by 
physician and institutional knowledge of how to bill for the assay. For institutions to 
receive adequate reimbursement, administrative billing or coding staff must have the 
knowledge and skills to accurately bill using several correct procedural terminal (CPT) 
codes. Frequently, billing and coding expertise is restricted by size and location of the 
institution. Although such expertise likely resides within large NCI CC or medical 
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centers with an academic affiliation, smaller community hospitals that have not been 
routinely obtaining genetic analysis of patient tumor tissue, might lack this expertise.   
Roger’s framework does not include cost in his discussion of attributes of the 
innovation. Particularly in the US healthcare system, there has been increased emphasis 
on the need to control the rising costs of healthcare. Providers are becoming increasingly 
aware of the cost of innovations and this may impede adoption and diffusion of the 
innovation.  
Roger’s framework also does not consider the timing and role of professional 
associations such as National Cancer Center Network (NCCN) or American Society of 
Clinical Oncology (ASCO) in their issuance of clinical practice guidelines.  When there 
is a delay in the issuance of guidelines by such organizations, or when there is vacillation 
or uncertainty in the clinical utility of a health innovation, this confusion and uncertainty 
may significantly delay diffusion.  The EGFR assay experienced both types of delays.  
There was confusion around the methodology for testing and whether patients lacking an 
EGFR mutation also benefited from and EGFR TKI. These were a factor in the pace of 
diffusion. In some cases, delays in diffusion may benefit patients by allowing better 
evidence to develop which may contradict the enthusiasm often generated from early 
results of innovation.   
A recent review by Soleimani & Zenios (2011), suggested that the regulatory and 
reimbursement systems of the US contribute to incremental rather than disruptive 
approaches to innovation. They suggested that in some cases disruptive innovations may 
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have a greater impact on patient care. The framework by Christensen and Raynor 
(Christensen & Raynor, 2003) emphasized that while provider markets have seen 
disruptive innovation, patient markets have not. The example provided is the invention of 
cardiac stents, which essentially allowed interventional radiologists to compete with 
cardiac surgeons (Soleimani & Zenios, 2011). The innovation in the provider market 
increased competition for patients by two separate groups of providers competing for 
patients.   
Lacking in the Soleimani & Zenios (2011) analysis is a discussion about the role 
principal-agent theory may have in the feasibility of disruptive innovations in patient 
markets. Principal-agent theory is an economic and legal concept in which a principal 
(the patient) delegates, either by choice or by necessity, authority to an agent (the 
physician) to make decisions about which healthcare services will be performed.  This 
principal-agent theory is very applicable and relevant to the conceptual model of studying 
diffusion of the EGFR assay.  As long as a physician referral/prescription is required to 
obtain access to and reimbursement for the EGFR assay, the physician and third party 
payer serve as gatekeepers to adoption, utilization, and successful diffusion of the EGFR 
assay. Whether physicians need to recommend patient access to the EGFR assay is in 
important consideration, one which will be taken up in the conclusion and implications 
section of this paper.  
Given that diffusion of the EGFR assay is restricted by both patient choice and 
physician referral, which may be further restricted by institutional characteristics, 
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knowledge about reimbursement, or policies for implementing clinical practice 
guidelines, there are a few ways to measure successful diffusion of the EGFR assay. One 
measure of diffusion is the number of institutions that have adopted the assay. For 
purposes of this analysis, whether an institution has placed a single order for the EGFR 
assay for a patient in 2010 will be considered what Roger’s diffusion theory calls 
adoption of that innovation (Rogers, 1962). Continued utilization and dissemination of 
the innovation is measured as the aggregated usage rate across institutions within each 
county relative to the annual number of lung cancer cases in that county that guidelines 
recommend receive the assay. That is defined as the utilization rate.  For purposes of this 
analysis, the primary measures of diffusion are: whether institutions ordering the assay, 
the aggregated county level utilization rate, and the penetration rate, defined as the ratio 
of institutions ordering the assay relative to number of hospitals within county.  These are 
defined in detail in Chapter 4.  
Figures 1, 2, and 3 illustrate how significant findings of the literature were 
incorporated into Roger’s diffusion of innovation theory. Figure 1 is the normal curve of 
distribution with adopters of innovation categorized according to Roger’s theory.  It 
illustrates my hypothesis of where in the process of diffusion hospitals fall based on 
institutional and regional characteristics. Consistent with the theory, the EGFR assay was 
developed by an NCI CC.  Therefore, NCI CCs are in the innovator category. The 
academic medical centers (AMCs) which do not necessarily have NCI designation but 
participate in similar types of clinical cancer research are likely to be early adopters of 
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innovation. Neighboring hospitals in well educated, high income metropolitan counties 
surrounding the NCI CCs and large AMCs are likely to be in the early majority.  
Hospitals distant to the NCI CCs, located in non metropolitan counties, and categorized 
as critical access hospitals are expected to be within the late majority or laggards in 
adoption of innovation. 
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Figure 1 
Proposed Categories of Adoption by Types of Acute Care Hospital 
 
Notes: Illustrates the hypothesized impact that hospital and regional characteristics have 
on stage of adoption of new technologies 
Source: Adapted from Rogers (1962)  
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Figure 2 illustrates the raw data provided by Genzyme Genetics graphed using the 
logistic function to illustrate the s-curve of diffusion.  The thick line is a forecast using 
the actual data from 2010.  The parameters which determine the curve’s shape are the 
date the innovation was introduced to the market and the date it reaches market 
saturation.  The parameters used for this model were a 12.36% market penetration in year 
2010 and by year 2018 it would reach market saturation with 80% of the eligible patients 
receiving the assay. This alpha value, which is the rate at which the function grows, is 
.30. The curve increases based on the expected number of adopters at each point.  The 
inflection point is the year of greatest adoption, when the technology diffuses to greater 
than 50% of the population and the slope of the line moves toward 0. Several 
assumptions, upon which this graph is based, are debatable. However, the purpose is to 
illustrate the concepts of the adoption and diffusion curves.   
The thin line shows the shape of the curve if healthcare providers were 
implementing evidenced based guidelines and recommending the assay to the majority of 
patients. The curve may peak in year 2014 when other technologies such as next 
generation sequencing platforms are developed.  The dotted line shows the shape of the 
curve if there is continued lack of adherence to guidelines.  This may happen if there was 
growing evidence that erlotinib was beneficial to all patients rather than just with those 
who have an EGFR mutation.  Providers may then believe there is no use for the assay 
and continue to prescribe erlotinib in the second or third line.    
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Rogers often gets credit for the s-curve of diffusion but it was actually economist 
Ayers (1989) who illustrated that diffusion of innovation follows a logistic function S-
curve.  Rogers (1962) framework proposed that adopters of innovation fall along a 
normal distribution, which he categorized as innovators, early adopters, early majority, 
late majority and laggards. This curve also illustrates a concept which was popularized in 
healthcare by the Institute of Medicine (IOM) but which was originally proposed by 
Geoffrey A. Moore in his 1991 book entitled Crossing the Chasm (Moore, 1991). Moore 
analyzed adoption of information technology products. The IOM applied Moore’s 
theories to analyze differences in the delivery of quality healthcare services. The IOM 
proposed that differences in quality exist due to delay in implementation of innovation 
and evidence based medicine to the overall population. The chasm refers to the time 
period between when the innovation is used by early adopters (which in my model would 
be the NCI CC and large AMCs) to when it is disseminated to the early majority. This 
time period coincides with the inflection point, which is halfway to market saturation. 
The number of adoptions per year peak at the inflection point and the slope of the 
diffusion curve moves toward 0.  An important point is that Moore viewed this s-shaped 
curve as applicable to disruptive technologies which result in a significant change of 
behavior.  There are many researchers which believe regulatory, reimbursement, and 
physician practices make disruptive innovations in healthcare difficult.   
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Figure 2 
Diffusion of EGFR Testing Based on Genzyme Genetics Claims  
  
 
Notes: Thick line is logistic function assuming time 1 at 2010 of 12.36%, time 2 at 2018 
at 80% and alpha .39. Thin line illustrates more rapid diffusion. Dotted line illustrates 
slower diffusion. 
Source: Authors theoretical construction 
 
In the discussion about lung cancer disparities research, one finding was that 
many lung cancer patients are denied access to evidenced based care that recommends 
patients undergo an invasive biopsy prior to diagnosis. I noted that if patients do not 
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additionally preventing access to the EGFR assay.  Figure 3 illustrates two hypothesized 
pairs of curves. The s-curves of diffusion that crosses the y axis at year 2002 with the 
adoption curve at 10% are for diffusion of the guideline recommending invasive biopsy 
to diagnosis lung cancer. The diffusion and adoptions curves to the right are for the 
EGFR assay.  This illustration is meant to show how diffusion and adoption curves of the 
EGFR assay are restricted by the adoption and diffusion curves of invasive biopsies. 
According to these hypothesized curves, in 2010 only 70% of lung cancer patients 
underwent invasive biopsy.  Therefore, only those patients would have access to the 
EGFR assay.   
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Figure 3 
Compounding Effect of Differential Rates of Diffusion 
 
Notes: Hypothesized diffusion and adoptions curves 
Source: Author’s theoretical construction 
Assumptions of the conceptual model 
The conceptual model assumes diffusion of the EGFR assay emanates from the 
NCI CC.  Therefore, prior to analyzing the institutional and regional factors associated 
with adoption and diffusion of the EGFR assay, I analyze the regional factors associated 
with a county having an academic medical institution that obtains NCI designation. 
Having isolated those factors, I then measure the likelihood a hospital orders the EGFR 
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assay given its institutional and regional characteristics. Finally, I analyze the rate of use 
of the EGFR assay, calculated as the number of assays ordered in the county divided by 
the annual number of guidelines directed lung cancer cases in that county. Adoption is 
defined in this study as a hospital having ordered at least one EGFR assay from Genzyme 
Genetics. This analysis will be conducted at the institutional level and by whether the 
institution is located within the same county as an NCI CC.  The county rate of utilization 
of the EGFR assay refers to the number of EGFR assays ordered relative to the number of 
lung cancer cases within the county.  This analysis will also be conducted by whether 
there is an NCI CC within the county or not.  
It is worth noting that county characteristics that positively influence the 
utilization rate in counties without an NCI CC, may, in some cases have the opposite 
effect in counties with an NCI CC. For example, the average age of diagnosis of lung 
cancer is age 71.  Although patients under the age 45 can be diagnosed with lung cancer, 
the vast majority of patients are diagnosed after age 45.  The lung cancer disparities 
research has revealed that patient populations most likely to undergo an invasive 
procedure to obtain tumor tissue or surgical resection are nonminority patients, with 
higher education and incomes. Therefore, metropolitan counties with urban centers have 
a high percentage of young minorities which positively influence the location of an NCI 
CC. Yet, those same characteristics may contribute to a lower utilization rate because 
young minorities are not often diagnosed with cancer.  
The different dependent variables for each stage of the model are: 
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Table 1 
 
Dependent Variable in Each Stage of the Conceptual Model 
 
Equation Dependent Variable Measured 
1 Is there an NCI CC in the county 0/1 - No/Yes 
2 Did the hospital order the EGFR assay 0/1 - No/Yes 
3 County EGFR adjusted utilization rate 0-1* 
Notes: * Presumes assay is conducted during initial diagnosis rather than reflexive testing 
of patients diagnosed in prior years. Further presumes cross county utilization is limited. 
Source: Author’s construction 
 
It is also necessary to explain that, although this study analyzes diffusion of the EGFR 
assay, the literature reviewed suggests persistent institutional and regional differences in 
patient access and utilization of older innovations and clinical practice guidelines in the 
treatment of lung cancer.  These persistent differences in older technologies will also 
contribute to a slower rate of diffusion for the EGFR assay.   
In the US healthcare system, current policy does not consider the cost benefit 
analysis of medical interventions.  Therefore, in theory, all patients diagnosed with 
NSCLC, for whom guidelines recommend lung tumor genotyping, should have access to 
the EGFR assay. However, as described in Figures 2 and 3, if patients are not provided 
access to advanced technologies for conducting lung tumor tissue biopsy, such as 
mediastinoscopy, access to and diffusion of the EGFR assay is restricted. Further, if 
institutions have not been exposed to the benefits of treating patients with an EGFR TKI, 
they are less likely to understand the importance of conducting lung tumor genotyping.  
So, although in theory all guideline recommended NSCLC patients should have access to 
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the EGFR assay, the reality is that a large segments of the population will be denied 
access because they live in remote parts of the country that do not have acute care 
hospitals or because they obtain care at critical access hospitals (CAHs) that may not 
provide advanced cancer care services. Further, as many as 10% of the lung cancer 
patients offered biopsy or surgery refuse to undergo these invasive procedures. Table 2 
provides a reasonable estimate of the 2010 population that could have had access to the 
EGFR assay. 
Table 2 
Estimate of Patient Population that Could Access to the EGFR Assay 
 
CDC/NPCR 
Number of incident lung cancer cases in 2010       208,603  
NSCLC is 85% of lung cancers       177,313  
Routine testing for squamous cell not recommended        (35,463) 
Guideline recommended testable population       141,850  
Patients in 503 counties that have no acute care hospitals         (7,403) 
10% of patients offered biopsy or surgery for lung cancer refuse       (20,860) 
Estimate of 2010 testable population       113,587  
Notes:  Incidence number derived from the National Program of Cancer Registries 
(NPCR) and Centers for Disease Control and Prevention (CDC) State Cancer Profiles in 
2011.  
Source: Author’s construction 
 
 With a testable population of 113,587 and Medicare paying between $622.58 and 
$836.01 per test, it would cost the country approximately $70 million dollars a year to 
test all guideline directed lung cancer patients for an EGFR mutation. Most of these 
patients are over age 65, which generates debate about whether genomic analysis of all 
these patients is a cost effective intervention. In countries with publicly funded national 
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medical care, medical interventions must meet a maximum threshold of cost per life year 
saved.  There is considerable debate in the US whether the rising cost of healthcare as a 
percentage of growth domestic product will require a similar cost benefit analysis of 
medical interventions be implemented in this country. The cost effectiveness of 
molecular diagnostics such as the EGFR assay is achieved by identifying the specific 
segment of the population that will benefit from the targeted therapy.  In an environment 
in which the EGFR assay is not used, the EGFR TKI is often prescribed to patients that 
will achieve no benefit.  The cost of erlotinib is approximately $2000 per month, more 
than twice the cost of the EGFR assay. If all 113,587 guideline directed lung cancer 
patients were being prescribed erlotinib for one month, this would cost the government 
approximately $227 million. If only the 15% of patients with an EGFR mutation were 
being prescribed erlotinib, this would cost the government $34 million.  Therefore, the 
cost effectiveness of the EGFR assay, and many other molecular diagnostics identifying 
somatic mutations, is in cost savings that could potentially be achieved from limiting 
access to molecularly targeted drugs.  However, the US healthcare system has, to date, 
not restricted access to medical interventions based on cost or comparative effectiveness 
analysis. 
As discussed previously, a limitation of the dataset is incomplete information on 
the NCI CC utilization of the EGFR assay.  Twenty seven NCI CCs had ordered EGFR 
assays through Genzyme Genetics in 2010. However communication with some of these 
centers confirmed that the EGFR assay is often conducted within the NCI CC’s own lab 
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as part of a clinical trial protocol.  According to Genzyme Genetics, it contracted with 
four of the large, well established NCI CCs for whom it conducted the EGFR assay 
exclusively.  Information on the utilization within these NCI CCs was extrapolated to 
impute an estimate of overall utilization by NCI CCs.  Table 3 provides an estimate of the 
NCI CC utilization. The estimate was based on the actual usage by four NCI CCs. These 
NCI CCs had contracted with Genzyme Genetics to be the exclusive provider of the 
EGFR assay.  The utilization rate for these NCI CCs was between 15 and 50% of their 
annual lung cancer incidence. Therefore, we assumed that NCI CCs conduct EGFR 
assays on 30% of their county’s annual lung cancer cases. 
Table 3 
Estimate of Number of EGFR Assays Conducted at NCI CCs 
Number of annual lung cancer cases in 49 NCI counties      23,680  
Genzyme Genetics database has complete information on 4 NCI CCs.  
These 4 centers have a utilization rate between 15%-50% of their 
counties annual lung cancer cases. So, let’s assume NCI CCs have 
30% utilization rate 
 
 
 
     7,104  
 
 
 
Notes: Formula for imputed estimate: Summarize guidelines directed lung cancer cases in 
49 NCI counties and multiply by .30. Does not consider extensive border crossing that is 
likely taking place by patients outside of NCI counties seeking care within NCI CCs. 
Source: Author’s theoretical construction 
 
Table 3 suggests that use of the EGFR assay by the 62 comprehensive cancer centers 
exceeds use nationally by the 4,720 other acute care hospitals included in the database. 
While this underscores the limitations in the dataset, it also suggests significant 
underutilization of the assay. Table 4 provides an estimate of overall diffusion rate of the 
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EGFR assay for 2010.  This rate was calculated by taking the actual orders of the EGFR 
assay by non-NCI institutions and adding the imputed estimate of use by NCI CCs.   
Table 4 
Estimate of US Diffusion Rate of the EGFR Assay 
Actual utilization from Genzyme Genetics database excluding 
NCI CCs 
          6,936  
Estimated NCI CC utilization         7,104 
Proposed 2010 testable population (market size)       113,587  
Utilization rate = Number of tests/number of cancer cases            12.36%  
 
Notes: Estimated rate based on incidence rate in one year. Does not include reflexive 
testing for prior years.  
Source: Author’s theoretical construction 
 
This information makes it possible to illustrate how Rogers (1962) theory of 
diffusion informed the conceptual model analyzing adoption and utilization of the EGFR 
assay. 
Illustration of the Conceptual Model 
 
Figure 4 provides an illustration of the conceptual model. It is a two step approach 
with two measures of diffusion.  The first measure of diffusion is adoption of the assay 
by acute care hospitals. The second measure of diffusion is the county EGFR utilization 
rate.  
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Figure 4 
Steps in the Conceptual Model 
Equation 1      Equation 2 
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Equation 3 
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Hypotheses 
Most patients diagnosed with NSCLC are over age 65. Therefore, in a rational, equitable 
healthcare system, in which Medicare coverage reduces reimbursement barriers, the 
majority of NSCLC patients should receive quality medical care that is guided by the 
evidence reflected in clinical practice guidelines. Only a patient’s inability or 
unwillingness to pay the coinsurance or undergo an invasive tumor biopsy should restrict 
access to the EGFR assay. A review of the literature discussed within Chapter 2 suggests 
that whatever the research hypotheses listed below, the probability that the null 
hypothesis is correct is very low. 
Equation 1 hypotheses – Analysis of location of NCI CC 
As mentioned earlier, a key assumption of this conceptual model is that diffusion 
of the EGFR assay emanates from the NCI CCs.  Therefore, it is important to understand 
the regional factors associated with an academic medical center obtaining NCI 
designation. 
(1) Number of institutions within county affiliated with AMCs will have a 
positive effect on the likelihood there is an NCI CC within the county. 
(2) Metropolitan categorization will have a positive effect on the likelihood there 
is an NCI CC within the county. 
(3) Percentage of the county population that self identify as Black will have a 
positive effect on the likelihood there is an NCI CC within the county. 
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(4) Percentage of the county population with education of a bachelor’s degree or 
greater will have a positive effect on the likelihood there is an NCI CC within 
the county. 
(5) Percentage of the county population with income greater than $75,000 will 
have a positive effect on the likelihood there is an NCI CC within the county. 
(6) Percentage of the county population under age 45 will have a positive effect 
on the likelihood there is an NCI CC within the county. 
Equation 2 hypotheses – Likelihood any U.S hospital ordered EGFR assay 
As discussed in the introductory pages, it is believed that presence of an NCI CC 
in the county has a significant influence on the likelihood an institution will order an 
EGFR assay.  Therefore, the institutional and regional analysis will be conducted with 
NCI county as one causal factor. It should also be noted that the 60 clinical care NCI CCs 
are located within 49 counties. Institutional hypotheses are: 
(1) Annual cases of lung cancer within the county will raise the likelihood of 
institutions ordering an EGFR assay. 
(2) Whether an NCI CC is present in the county or not, participation in an NCI 
clinical research cooperative group has a positive influence on the likelihood 
it orders the EGFR assay. 
(3) Institutional capabilities to provide cardiothoracic surgery, chemotherapy and 
advanced imaging (Pet Scan) increase the likelihood it orders the EGFR assay. 
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(4) Affiliation with an AMC has a positive influence on likelihood it orders the 
EGFR assay. 
(5) Distance between the hospital and NCI CC will have an inverse relationship to 
the likelihood the institution orders the EGFR assay.  
(6) Location within a metropolitan county will have a positive effect on the 
likelihood of ordering EGFR assay. 
(7) Within non NCI CC counties, the percentage of the population that is Black 
will have a negative effect on the likelihood the institution adopts the EGFR 
assay. 
(8) Institutions located in counties in which there is a large percentage of the 
population with education of a bachelor’s degree or greater, will have a 
positive effect on the likelihood it orders the EGFR assay. 
(9) Institutions located in counties in which there is a large percentage of the 
population with income above $75K will have a higher likelihood it ordered 
the EGFR assay. 
Equation 3 hypotheses – Regional factors influencing EGFR utilization rate 
(1) NCI CC within county will suppress EGFR Presence of NCI CC in county 
will suppress EGFR utilization rate due to lack of NCI CC data 
(2) Whether an NCI CC is present in the county or not, number of institutions 
within a county participating in NCI cooperative clinical research groups will 
have a positive effect on the rate of EGFR assay utilization. 
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(3) Number of institutions within county affiliated with AMCs will increase rate 
of EGFR assay utilization 
(4) In non NCI counties, location within a metropolitan county will increase rate 
of EGFR assay utilization.  
(5) In non NCI counties, the percentage of the population that is Black will have a 
negative effect on the rate of EGFR assay utilization.  
(6) In non NCI counties, the percentage of the population with education of a 
bachelor or greater will have a positive effect on the rate of EGFR assay 
utilization.  
(7) In non NCI counties, the percentage of the population with Income greater 
than $75,000 will have a positive effect on the rate of EGFR assay utilization.  
(8) In non NCI counties, the percentage of the population that is under 45 will 
have a positive effect on the rate of EGFR assay utilization.  
Significance 
This dissertation research is significant from a number of different perspectives: 
Studying differential rates of access to lung tumor genotyping may elucidate factors that 
have contributed to persistent socioeconomic and structural differences in diagnosis, 
treatment, and outcomes in lung cancer. Identifying barriers that exist in access to the 
EGFR assay may help inform the implementation of evidence based clinical practice 
guidelines and translational research in other areas of health innovation. Nurses, as 
administrators, clinicians, educators, policy analysts, and researchers, are on the forefront 
 40 
 
of implementing healthcare innovations. Understanding the process of diffusion is a 
critical component to successful dissemination of innovation. Further, the nursing 
discipline itself is currently undergoing significant change and innovation within its own 
professional practice. Analyzing diffusion of a cancer diagnostic technology will inform 
nurse researchers of the tools required to successfully implement, measure, and monitor 
the dissemination of innovations within the nursing discipline.  
Contexts 
This section establishes the background in which this research question was 
generated. It provides a brief overview of the development, commercialization, and 
licensing of the EGFR assay. Further, it provides the traditional health policy framework 
analysis of the historical, political, sociological, economic perspectives of the federal 
government’s role in the development and funding of cancer diagnostic and treatment 
technologies clinical trials. 
Background on development of the research question  
 The impetus for this research study was generated in 2007 when the Director of 
Equity at Dana Farber Cancer Institution and Harvard Comprehensive Cancer Center 
(DF/HCC) described a growing perception among thoracic oncologists that erlotinib was 
not as effective in Blacks as it was in Whites due to a lower incidence of EGFR 
mutations in Black lung cancer patients. At the time, there was one paper published 
which had oversampled Blacks to get 50 patients in study who self identified as Black. It 
reported an incidence rate of EGFR mutations in Blacks as 2.4% or 1 patient (Yang et al., 
 41 
 
2005).  Being familiar with the well established research documenting the problems of 
under representation of minorities in cancer clinical trials and at NCI CCs, I questioned 
whether there was enough evidence in the EGFR TKI clinical trials to substantiate the 
belief that EGFR mutations in Blacks is rare. In effort to investigate this, I contacted 
several leading thoracic oncology principal investigators at NCI CCs to request 
information about the number of Blacks enrolled in EGFR TKI clinical trials and 
biomarker studies. Five of the country’s leading thoracic oncologists, who were also 
active principal investigators in the EGFR TKI clinical trials, reported that few Blacks 
were enrolled in the EGFR TKI treatment or biomarker clinical trials. The student 
researcher then questioned whether there was also under representation of lung tumor 
tissue from Blacks in tissue banks. Pathologists responsible for overseeing large NCI 
funded lung tumor tissue banks reported that only recently had tissue banks begun to 
record ethnicity and race of patients’ tumor tissue in their anonymous tissue bank.  From 
this limited qualitative/investigational approach, the student developed her main research 
interest which was investigating whether the patterns of enrollment of patients in lung 
cancer clinical trials contributes to growing gap in lung cancer outcomes among poor and 
minority patients.  
Development, commercialization, and licensing of the EGFR assay 
In April 2004, two research groups at the federally funded NCI CC, DF/HCC, 
proved the link between clinical responsiveness to an EGFR TKI and a mutation in the 
EGFR receptor (Lynch et al., 2004; Paez et al., 2004). This discovery lead to the 
 42 
 
development of the EGFR assay.  By September 2005, DF/HCC and its investigators sold 
the worldwide rights to market and distribute the EGFR assay to Genzyme Genetics 
(Genzyme Genetics, 2005). In February 2008, Genzyme Genetics sublicensed the 
worldwide rights, with the exception of North America and Hong Kong, to DxS, a 
company based in the UK. This company, in collaboration with Astra Zeneca, had 
developed and was marketing its own version of the EGFR assay (Genzyme Genetics, 
2008) and was marketing it in Europe for use as a companion diagnostic in combination 
with Astra Zeneca’s EGFR TKI gefitinib. In 2009, Genzyme Genetics expanded the 
license with DxS to include the US market.  However, during this time, DxS was in a 
dispute with Roche Diagnostics over the rights to its EGFR mutation detection kid. 
Further, DxS was in the process of being acquired by a larger UK based company, 
Qiagen. Therefore, DxS’s focus on the marketing and distribution of the EGFR assay in 
US was minimal.  According to Genzyme Genetics, the agreement with DxS did not 
make any meaningful contribution to the number of EGFR assays sold in the US market. 
By late November 2010, Roche Diagnostics, one of the largest, publically traded 
diagnostic and pharmaceutical companies in the world, also sublicensed from Genzyme 
Genetics, the worldwide rights to market and distribute the EGFR assay. Following this 
transaction, LabCorp, a large, publically traded clinical research organization, announced 
its intention to acquire Genzyme Genetics.   
Frequent licensing, acquisitions, and merger activity is common for companies 
and technologies that are early in the s-shaped diffusion curve, particularly when there is 
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a belief or perception that the slope of the curve is about to increase rapidly. Such 
commercialization may also lead to better access for poor and minority patients because 
diffusion of the innovation may become disruptive rather than the slower, incremental 
approach that takes place in the initial stages of federally funded translational research.  
An important question health service researchers need to consider is, given that 
many innovations in cancer treatment are developed by institutions supported by federal 
taxpayer funds, whose responsibility is it to ensure that: 1) Development of health 
innovations are informed by diverse patient populations. 2) Minority and poor patients 
achieve the same timely benefit from health innovations as patients who routinely seek 
care at the institutions developing these innovations. The following section discussed the 
federal government’s investment and commitment to these issues. 
Federal government’s sponsorship of cancer clinical research 
Historically, the federal government has provided substantial financial and 
political support for cancer research and care.  This support began with the 1930 passage 
of the Ransdell Act creating the National Institute of Health (NIH), authorizing the 
establishment of fellowships for research into basic biological and medical problems, and 
regulating new drug development (Starr, 1982). In 1937, Congress authorized the 
creation of the NCI along with Public Health Service, which funded cancer research in 
both its own labs as well as outside labs. Ten years later, NCI reorganized to provide an 
expanded program of intramural cancer research, grants, and cancer control activities 
with appropriations to the states and AMCs for their support of cancer control activities.  
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The investment and coordination from the Federal Government in clinical 
research catapulted clinical trials to a new level.  Indeed some researchers cite the 1940s 
through the 1960s as the golden years of clinical research (Swazey & Fox, 2004). 
Involvement by the federal government enabled the development of large scale clinical 
trials across geographically diverse populations.  By 1954, NCI established a full-scale 
clinical research program through sponsorship of multicenter clinical trials cooperative 
groups, of which the leading academic research centers were members.  The following 
year, NCI organized the first solid cancer cooperative group, the Easter Cooperative 
Oncology Group (ECOG), which became the largest cooperative group consisting of 
4000 members. By 1960, most phase II and phase III clinical cancer trials were devised 
and administered by the NCI.  By 2000, there were more than 10,000 investigators and 
3,000 institutions registered with NCI (Keating & Cambrosio, 2002).  
The rise of evidenced based medicine (EBM) has elevated the recognition and use 
of clinical research to a prominent level in healthcare.  Randomized control trials (RCT) 
are now considered the gold standard in the hierarchical evaluation of clinical evidence. 
Despite the significant federal investment and rapid expansion of clinical 
research, throughout the 1980s and 1990s, there was a lack of minority and elderly 
participation in cancer clinical trials.  In 1993, the NIH, recognizing failures in the 
healthcare system to provide access for women and minorities to clinical research, 
established the Revitalization Act of 1993. This Act was mandated by Congress in 
Section 492B of Public Law 103-43. Congress sought to establish an ethical principal of 
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justice, emphasizing the importance of balancing the burden of research with its benefits 
(NIH, 2008). Prior to enactment of the NIH inclusion policy, several incidents of 
unethical treatment of patients in clinical research, most notably the Tuskegee syphilis 
trials that took place from 1932 until 1972, and the 1977 thalidomide trials in pregnant 
women, resulted in researchers becoming overly cautious about recruiting minorities and 
women in clinical research (Killien et al., 2000).   
Despite the passage of the 1993 Revitalization Act, lack of enrollment of 
minorities and elderly persisted. Uncertain coverage by third party payers, including 
Medicare, was believed to be the primary reason for lack of participation.  To address this 
problem, on June 7
th
, 2000, President Clinton announced that Medicare would begin to 
pay for the routine costs of care for beneficiaries enrolled in federally sponsored clinical 
trials (Iltis, 2005).  This announcement further expanded the federal government’s 
investment in cancer clinical trials.  This commitment was reinforced with the Center for 
Medicare & Medicaid Service’s (CMS) October 17th, 2007 announcement that it would 
continue coverage of clinical trials. In 2007, cancer represented the largest portion of 
NIH’s investment equaling $4.754 billion or 16.6% of the budget (OMB, 2007). While 
great strides have been achieved in the enrollment of women and elderly in cancer 
clinical research, the lack of enrollment of minorities persists. Some researchers cite the 
federal government’s role in the Tuskegee Syphilis experiments as a significant factor 
influencing Black patients trust of the medical establishment overall, especially with 
participation in clinical research (Shavers, Lynch, & Burmeister, 2002).  However, other 
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researchers have demonstrated that racial differences are less significant when access to 
treatment is adjusted by socioeconomic factors (Gross et al., 2008).    
A paradigm shift in the approach to cancer clinical trial research and drug 
development began to take place in the late 1990s with the approval of trastuzumab for 
patients with Her2+ breast cancer in 1998.  This is generally recognized as the beginning 
of the era of personalized medicine in which academic researchers and drug companies 
began considering whether subgroups of patients may obtain more benefit from treatment 
than others. In 2001, gefitinib, an EGFR TKI, began to show anti tumor activity in 
advanced NSCLC.  By 2003, gefitinib was approved by the FDA for advanced NSCLC 
and there were some indications that response rate varied based on patient ethnicity 
(Fukuoka et al., 2003). One of the significant limitations to research that took place from 
2001 through about 2008 was that lung tumor tissue analysis was conducted 
retrospectively often after patients had already begun participating in the treatment 
clinical trial.  In many cases, a second research study was conducted subsequent to the 
termination of the treatment clinical trial.  Nearly all researchers recognized the 
limitations to this research approach. There was growing support for biomarker research 
to be conducted concurrent with the treatment trial or prospectively in the lab.   
The epidemiologic approach of enrolling large cohorts of patients into treatment 
clinical trials fails to account for genomic variations in tumor tissue. The hope and 
promise of personalized medicine is that patients will be treated based upon the 
molecular profile of their specific tumor tissue.  However, such an approach increases the 
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burden of accruing the right numbers of patients into the various arms of a clinical trial.  
Further, it places increased urgency on the need to recruit a diversity of patients.   
Recently, the leaders of NIH and the Food and Drug Administration (FDA) 
discussed their vision to makes changes to their regulatory and funding structures to 
prioritize a personalized approach to medicine (Hamburg & Collins, 2010).  As part of 
this approach, the NIH and the FDA will: 
1) Invest in advancing translational and regulatory science 
2) Define regulatory pathways for coordinated approval of codeveloped 
diagnostics and therapeutics 
3) Develop risk-based approaches for appropriate review of diagnostics to more 
accurately assess their validity and clinical utility, and make information 
about tests readily available. 
Hamburg and Collins (2010) also emphasized that for personalized medicine to succeed, 
it will require the FDA and NIH to expand their efforts to develop tissue banks 
containing specimens that will allow for broader assessment of the clinical importance of 
genetic variation across a range of conditions along with information linking them to 
clinical outcomes. They emphasized that this may require public–private partnerships to 
help move candidate compounds into commercial development.  
 Some researchers have cited the importance of companion diagnostics, which are 
packaged diagnostic kits such as the DxS kit described above. Companion diagnostics 
require FDA approval, as opposed to diagnostic assays like the one developed at 
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DF/HCC which need to be performed in laboratories approved by Clinical Laboratory 
Improvement Amendment (CLIA) for high complexity testing. DF/HCC is part of a 
group of leading AMCs that developed the Lung Cancer Mutation Consortium Protocol 
to conduct molecular analysis for a broad range of somatic mutations, some which are not 
yet clinically actionable, using multiplex mutational profiling system. As part of this 
protocol, all patients are screened for participation in tumor tissue analysis and it is an 
opt-out decision to not participate. This background is discussed in greater detail in 
chapter 2.  
Definition of terms 
In this paper, there are several specialized terms related to the process of 
obtaining and analyzing lung tumor tissue for diagnosis and treatment of lung cancer.  
Most of the definitions provided here were obtained from an NCI online resource: 
http://www.cancer.gov/dictionary.   
Term Definition 
Bronchoscopy An invasive procedure that uses a bronchoscope to examine the inside 
of the trachea, bronchi (air passages that lead to the lungs), and lungs. 
A bronchoscope is a thin, tube-like instrument with a light and a lens 
for viewing. It may also have a tool to remove tissue to be checked 
under a microscope for signs of disease. The bronchoscope is inserted 
through the nose or mouth. Bronchoscopy may be used to detect 
cancer or to perform some treatment procedures.  
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Term Definition 
 
EGFR assay 
 
A laboratory test to detect a mutation in the epidermal growth factor 
receptor.  
EGFR mutation  The genetic change in a lung tumor that has been identified as 
sensitive to a pharmacogenomic medication such as gefitinib (used 
outside the US) and erlotinib. 
Endobronchial 
ultrasound-needle 
aspiration  
(EBUS-NA) 
 
 
 
Endoscopic ultrasound-
needle aspiration (EUS-
NA) 
Invasive procedure to biopsy the mediastinal, hilar and interlobar 
lymph nodes. Endobronchial ultrasound enables very accurate 
localization of the extrabronchial structures, including vessels (using 
the power Doppler imaging) and lymph nodes. Using 10—40 mmlong 
needles makes a biopsy of nodes located in a relatively remote position 
from the bronchial wall possible (Szlubowski et al., 2010)(Szlubowski 
et al., 2009) 
A procedure which uses a thin, tube-like instrument that has a light 
and a lens for viewing, an ultrasound probe, and a biopsy needle at the 
end to obtain tumor tissue. It is inserted through the mouth into the 
esophagus. Also called EUS-FNA. 
Epidermal growth 
factor receptor 
The protein found on the surface of some cells and to which epidermal 
growth factor binds, causing the cells to divide. It is found at 
abnormally high levels on the surface of many types of cancer cells, so 
these cells may divide excessively in the presence of epidermal growth 
factor. Also called EGFR, ErbB1, and HER1.  
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Term Definition 
 
HER-2/neu intracellular 
domain protein   
 
The cytoplasmic domain or intracellular domain (ICD) of the 
HER2/neu protein that exhibits tyrosine kinase activity. Based on 
sensitization theory, co-administration of trastuzumab (anti-HER-
2/neu monoclonal antibody) and HER-2/neu intracellular domain 
protein may result in the potentiation of a HER2/neu-specific 
cytotoxic T lymphocyte (CTL) response against tumor cells 
overexpressing the HER2/neu protein. HER-2/neu protein, a 
glycoprotein cell surface receptor that is composed of an 
extracellular domain (ECD), a transmembrane domain, and an 
ICD, is overexpressed by many adenocarcinomas including breast 
adenocarcinoma. 
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Molecular diagnosis 
 
Mediastinoscopy 
 
 
 
 
 
 
Molecular marker 
The process of identifying a disease by studying molecules, such 
as proteins, DNA, and RNA, in a tissue or fluid. 
A procedure in which a thin, tube-like instrument with a light, lens 
for viewing, and tool for removing tissues is inserted into the chest 
through an incision above the breastbone. It is used to examine the 
organs in the area between the lungs and nearby lymph nodes and 
to get tissue sample from the lymph nodes on the right side of the 
chest. It is considered the gold standard for staging the 
mediastinum. 
A biological molecule found in blood, other body fluids, or tissues 
that is a sign of a normal or abnormal process. A molecular marker 
or biomarker may be used to evaluate body’s response to a 
disease. 
Personalized medicine A form of medicine that uses information about a person’s 
genes, proteins, and environment to prevent, diagnose, and 
treat disease 
Pharmacogenomics The process by which drug companies develop medications 
that target specific genetic changes in the tumor.  In 
pharmacogenomic drug development, clinical trials often 
require the medical institution to analyze tumor tissue. 
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Somatic mutation An alteration in DNA that occurs after conception. Somatic 
mutations can occur in any of the cells of the body except 
the germ cells (sperm and egg) and therefore are not passed 
on to children. These alterations can (but do not always) 
cause cancer or other diseases. 
Translational research A term used to describe the process by which the results of 
research done in the laboratory are used to develop new 
ways to diagnose and treat disease. 
Transbronchial needle 
aspiration (TBNA) 
A minimally invasive bronchoscopic technique that 
provides a nonsurgical means to diagnose and stage lung 
cancer by sampling the mediastinal and hilar lymph nodes 
through insertions of needle during a bronchoscopy.  
Transthoracic needle 
aspiration (TTNA) 
An invasive procedure in which a needle is inserted under the guide 
of a CT scan through the skin into a lung lesion to diagnose and 
stage lung cancer.   
Tyrosine kinase 
inhibitor  
A substance being studied in the treatment of some types of cancer. 
Tyrosine kinase inhibitor BIBF 1120 blocks enzymes needed for 
cells to grow, and may prevent the growth of new blood vessels that 
tumors need to grow. It is a type of tyrosine kinase inhibitor and a 
type of antiangiogenesis agent. Also called BIBF 1120. 
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CHAPTER 2 
As discussed in Chapter 1, four distinct bodies of literature informed the conceptual 
model that guided this research and hypotheses tested.  This chapter provides a critical 
review of each of these bodies of literature. 
Diffusion of innovation of healthcare services and technologies research 
Diffusion of innovation is the process by which a new idea, knowledge, or 
technology is adopted, communicated through the social network, and either 
implemented broadly to the point of market saturation, or until diffusion fails and the 
innovation is shelved or taken off the market. Although one of the earliest studies of 
diffusion was conducted in the 1950s and analyzed prescriptions of tetracycline by 
physicians (Coleman, JS. Katz, E. Menzel, H., 1966), most of the subsequent research 
involves applications to business or consumer technology markets rather than healthcare 
services (Soleimani & Zenios, 2011). Over the past decade, there has been increased 
attention to the relationship between diffusion of innovation in healthcare and differences 
in access and outcomes of healthcare services. This attention was generated by the 2001 
IOM publication, Crossing the Quality Chasm: A New Health System for the 21
st
 
Century, a title that is adapted from Geoffrey Moore’s analysis of Roger’s diffusion 
theory in the sentinel book Crossing the Chasm (Moore, 1991). Since its publication, this 
book has been considered required reading for business school students, particularly 
those who focus on entrepreneurship or marketing of products in the information 
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technology products.   Like Roger’s theory, it is a useful framework to consider. 
However, it lacks the complexities encountered when analyzing diffusion of healthcare 
services. The complexities of diffusion of innovation in healthcare services are discussed 
in a comprehensive review, commissioned by the National Health System in the United 
Kingdom (Greenhalgh, Robert, & Bate, 2008). One chapter in this publication discusses 
the fact that healthcare services are deeply rooted in an epidemiologic model of research 
and innovation. Such an approach relies heavily on rationalist and experimental 
approaches to evaluation of innovation with randomized clinical trials considered the 
gold standard (Greenhalgh et al., 2008).  The epidemiologic approach takes a linear 
approach to the adoption of innovation. It presumes that once the evidence is established 
through RCTs, new scientific knowledge, which could include a change in clinical 
practice, new drug or device, among other innovations, would be implemented into 
practice (Greenhalgh et al., 2008). The limitation of an epidemiologic mindset to 
diffusion is discussed by researchers who have evaluated the delays, and in some cases 
complete failures, of translational research to be incorporated into patient care. 
The term translational research has historically been used to describe the transfer 
of knowledge from basic sciences (bench) to produce new drugs, devices, and treatment 
options to improve patient care (bedside). It refers to the development and testing of new 
compounds, devices, treatment algorithms to establish an evidence base for regulatory 
approval, commercialization, and justification for reimbursement. Recognizing that 
historically many advances in basic sciences have been slow to become integrated into 
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improved clinical care, Dr. Zerhouni, the former Director of NIH, undertook an effort to 
reduce the silos that exist in academic medicine between laboratory and clinical 
scientists. In the seminal 2005 interview, Dr. Zerhouni described the funding of a new 
program entitled the Clinical and Translational Science Awards (CTSAs), a grant 
program to encourage academic medical institutions to improve collaboration between 
the lab and clinical research personnel (Zerhouni, 2005). Initially, academic clinical 
scientists were very excited about this initiative, hopeful that it would result in more rapid 
utilization of improvements in patient care. Just a few years later, in 2008, a commentary 
entitled, ―The Meaning of Translational Research and Why It Matters,‖ by Dr. Steven 
Woolf described the failures of a product driven approach of bench to bedside 
translational research, stating that the historical definitions of translational research are 
incomplete and a premature endpoint in the bench to bedside paradigm shift. Only half 
the patients in the US benefit from translational advances (McGlynn et al., 2003). 
Practice-oriented translational research, which is now being called T2 or TRIP 
(Translating Research to Practice), focuses on analyzing and overcoming barriers to the 
diffusion, dissemination, and adoption of clinical practice guidelines that incorporate T1 
advances to the community.  
In the case of the EGFR assay, T1 represents the period between 2004, linking the 
EGFR mutation to clinical responsiveness of the EGFR TKI, and the commercialization 
of the EGFR assay by Genzyme Genetics.  T2 is the establishment of evidence based 
guidelines linking technological advances to improvements in patient care with 
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regulatory and reimbursement approvals. T3 is implementation of those guidelines and 
knowledge for reimbursement by the clinicians at the bedside and by the administrative 
and coding staff at the hospitals.  T4 would be communicating information from 
successful diffusion back to researchers and those who conduct research that becomes the 
basis of clinical practice guidelines to inform prevention.  
As has already been discussed in the review of the conceptual model, there are 
multiple levels of barriers to diffusion of innovation in healthcare services, including, but 
not limited to: 1) Complex and uncertain regulatory and reimbursement structure. 2) Role 
of principal/agent relationship in the physician referral to the innovation. 3) Delays in 
evidence being incorporated in clinical practice guidelines and lack of implementation of 
those guidelines at both an institutional and physician level.  
The IOM recognized that some of these barriers were interfering with 
applications, developed as a result of sequencing the human genome, being incorporated 
into improvements in medical care, community and public health prevention, and 
treatment (Hernandez, Rapporteur, 2008). The IOM convened a workshop to discuss the 
issue and published a report of its findings. This report cited the work by Burke and 
colleagues (2006) who found that few promising genomic discoveries had resulted in 
actual applications in medicine.  This report also included comments from Dr. Annetine 
Gelijns, who emphasized that the diffusion of genomic interventions is likely to be 
powerfully shaped by sociocultural factors, whereby even if genomic interventions are 
covered by insurers, patients may decide to pay out of pocket because of concerns about 
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confidentiality and the potential for discrimination by employers and insurance 
companies.  This, in turn, raises concerns about equity—for example, about lack of 
access to these technologies for those who do not have the means to pay (Hernandez et 
al., 2008).   
Also presenting at this workshop was Brad Gray, who was then vice president of 
product and business development at Genzyme Genetics.  He described the specific 
problems that Genzyme Genetics had with diffusion of the EGFR assay.  
―There is a new paradigm for personalized medicine, however, one in which 
complex testing (some of which is genomic, some of which is proteomic, and 
some of which is other technologies) plays a central role in linking observation to 
tests and therapy. In such a paradigm, observation s followed by a test that 
provides specific information for better decision making. This, in turn, is followed 
by the action, which would be the therapeutic choice or regimen that leads to a 
predictable response, thereby breaking the cycle of trial and error‖ 
 
Referring directly to the experience Genzyme Genetics had with the EGFR assay, 
he wrote,  
 
―The company paid more than  it had ever paid for an intellectual-property license 
and quickly drove a test to market. Soon afterward publications emerged that 
seemed to question the utility of EGFR mutation testing for driving dosing. Since 
that time there has been disagreement about which is the correct biomarker to 
predict response to this class of drugs. In July 2006 the C-Path Institute 
announced an effort to try to resolve the question of biomarkers in NSCLC 
cancer, but results are not yet available. When this product was taken to market, 
only a small minority of NSCLC patients who received TKIs—probably less than 
5 percent—actually received the test, Gray said. The penetration is highest in the 
leading academic centers, where there is willingness and an ability to navigate the 
nuances of the emerging evidence. Community physicians, on the other hand, 
have generally been reluctant to adopt this approach. They are confused about the 
multiple-testing options, and they use what they consider clinical information 
(e.g., patient’s race, smoking habits) as a proxy for the mutation status. 
Furthermore, because TKIs are most often used as the last line of treatment in 
these patients, there is a reluctance to do a test that would suggest that certain 
patients will not respond. The company learned several things from this 
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experience. First, the connection between genetics and treatment is not always 
clear. Community physicians need education and assistance in understanding 
conflicting evidence. Robust clinical-utility data will be required to drive adoption 
by community physicians, who will continue to substitute work-around solutions 
when they are modestly effective.  Furthermore, community physicians are not 
inclined, in general, to deselect patients from treatment. A test that selects patients 
in is much easier to sell than one that selects out, especially when there are few 
alternatives for those patients, Gray said. The adoption curve for EGFR testing is 
still heading upward. While the EGFR mutation test has not been adopted as 
rapidly as a new drug therapy typically would be, the indicators are moving in the 
right direction. The National Comprehensive Cancer Network (NCCN) guidelines 
for non-small-cell lung cancer include the test, a point which Genzyme Genetics 
believes will help community physicians gain comfort with the utility of the test. 
Based on past experience, then, Genzyme Genetics has revised its criteria for 
bringing new personalized medicine tests to market. First, for the company to 
invest in a test, the test needs to represent the only reliable way. Third, because 
reimbursement in the testing sector of the health care system has traditionally not 
been based on value but on activity-based costing, the economics must support 
investment in clinical and market development. The reimbursement path must be 
attractive, either by virtue of its intrinsic coding or because there is the possibility 
of making a compelling case to be reimbursed on a different basis than activity-
based costs. Furthermore, the company will look for places to invest where 
intellectual property and know-how is available on an exclusive basis. In 
situations where only a non-exclusive product is offered, the company will not be 
able to justify the investment required to perform clinical research or to navigate 
the regulatory system.  (Hernandez et al., 2008). 
 
While Gray acknowledged the problem conflicting evidence poses for physicians when 
considering the adoption of new technologies, his analysis neglected to consider the role 
patients play in pulling an innovation through the market – even when there is conflicting 
evidence.  It appears that Genzyme Genetics relied on a strategy of pushing the 
innovation through the market, viewing oncologists as their customers.   
Although this is beyond the scope of this paper, an analysis of the breast cancer 
molecular diagnostic tests may illustrate an effort by the companies to market directly to 
breast cancer patients and survivors. Cancer patients, survivors, and caregivers can play a 
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powerful role in pulling innovations through the complex hurdles of regulatory and 
reimbursement barriers, getting physicians, who are slow to adapt to change, to adopt a 
new technologies.  
When a diagnostic test is covered by Medicare and there are clinical practice 
guidelines that recommend its use, if a patient asks their oncologist or surgeon to order a 
test, it becomes much more difficult for that provider to decline the request.  Gray’s view 
of the problem will be discussed in much greater detail in Chapter 4. 
Lung cancer clinical outcomes research 
Lung cancer is the leading cause of cancer-related mortality for both women and 
men in the U.S. and worldwide. There are 1.35 million new cases and 1.2 million deaths 
yearly worldwide due to lung cancer (Parkin, Bray, Ferlay, & Pisani, 2005). In the US in 
2010, there were 222,520 new cases of lung cancer and 157,300 people died as a result of 
lung cancer (Jemal, Siegel, Xu, & Ward, 2010). Lung cancer represents 14.5% of cancer 
incidence and 29% of cancer deaths in the US. 
Platinum-based chemotherapy doublet is the standard care for most patients who 
present with late stage disease. This treatment offers patients modest improvements in 
survival (Schiller et al., 2002). However, in the past two decades, there have been 
significant advances in the understanding of lung tumor biology and molecular changes at 
the genetic level that contribute to oncogenesis. Although this understanding has not yet 
lead to significant increases in overall survival, for patients with specific genetic 
mutations or translocations, it has increased progression free survival. Continued 
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advances in the understanding of lung tumor oncogenesis will increase personalization 
and treatment of lung cancer with targeted drugs based on specific genetic abnormalities.  
In 1981, it was discovered that the EGFR receptor was overexpressed in several 
cancers, including lung cancer (Kawamoto et al., 1983).  By 1990, the class of drugs 
known as EGFR TKIs was discovered.  In 2002, oncologists and researchers began 
publishing information about their growing knowledge of the molecular biology of lung 
tumors and the significant role of EGFR mutations in the development and progression of 
NSCLC.  This same year, the first EGFR TKI, gefitinib, was approved in Japan. By 2004, 
international clinical trials of EGFR TKIs established a link between improvements in 
progression free survival and presence of an EGFR mutation in patients’ lung tumors. 
Retrospective molecular tissue analysis of these clinical trials contributed to the 
development of the EGFR assay. Patients who had EGFR mutations had a higher 
response rate and longer progression-free survival when their treatment paradigm 
included erlotinib or gefitinib (Lynch et al., 2004; Paez et al., 2004; Shepherd et al., 
2005).  However, patients without EGFR mutations responded poorly to erlotinib and 
gefitinib (Mok et al., 2009). Mutations in the tumor suppressor gene (p53) and activation 
of the Kirsten-Rous sarcoma virus (K-ras) oncogene were associated with poorer 
prognosis (Eberhard et al., 2005; W. Pao & Miller, 2005; Tol et al., 2009). KRAS 
incidence rate is thought to be between 20-30% in NSCLC patients and there are 
currently no targeted treatment options for KRAS mutations.  
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Although previous studies provided evidence that incidence of EGFR mutations 
varies with patient ethnicity, gender, and smoking status (Fukuoka et al., 2003; Jackman 
et al., 2007; W. Pao & Miller, 2005), more recent studies indicate that clinical 
characteristics are limited predictors of mutational status. If only women who were never 
smokers were tested for EGFR mutations, 57% of all EGFR mutations would be missed 
(D'Angelo et al., 2011). EGFR mutations have often been reported to be approximately 
15% in Whites, 2-3% in Blacks, and 20-30% in Asians living in the US (Calvo & 
Baselga, 2006; Leidner et al., 2009; Mok et al., 2009; Yang et al., 2005). However, the 
recent evidence weakening the relationship between smoking status and incidence of 
mutation, underscores the importance of including a large and diverse patient population 
in biomarker clinical trials. Clinical practice should not be based on incomplete or 
inaccurate anecdotal assumptions developed by a limited patient population enrolled in 
clinical trials. It also emphasizes the importance of providing access to lung tumor 
genotyping for all patients with adenocarcinoma of the lung.  
More recently, there was a discovery that patients with a translocation in the 
echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase 
(EML4-ALK) have a 52% response rate to an ALK inhibitor crizotinib (Kwak et al., 
2010). According to Ding et al. (2008) and Pao & Girard (2011), as of January 2010, the 
following mutations were known in NSCLC: HER2, PIK3CA, MET, BRAF, MAP2KI, 
and AKT1, which are thought to have a less than 5% incidence rate each, ALK and 
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EGFR which are thought to have between 5-15% incidence rate each, KRAS and yet to 
be discovered mutations have a 30% rate each.  
Even with these promising advances, the prognosis for patients with lung cancer 
is dismal, complicated by the fact that the disease is most often diagnosed in late stages 
when the cancer has spread beyond the lungs.  This is illustrated by the fact that over 
60% of lung cancer patients are diagnosed with advanced disease at stage III or stage IV 
(Ries et al, 2008).  
While there have been improvements in the rate of short-term survival, according 
to the NCI Surveillance, Epidemiology, and End Results (SEER) Program (2008), these 
have not been translated into significant improvements in long-term survival. In 1975, 
36.7% of patients survived 1 year. By 2004, this rate improved to 43.3%.  The five and 
ten year survival rates have not seen significant improvements.  In 1975, 13% of patient 
survived 5 years. By 2004, this rate only improved by 3.2% to 16.2% of lung cancer 
patients living to 5 years. When this analysis is extended to 10 year survival, there has 
only been a .8% improvement with 9.2% of patients in 1975 surviving 10 years and 10% 
of patients in 2004 surviving ten years.   
The five-year survival rate for patients diagnosed with lung cancer is even worse 
worldwide.  It is 15% for those living in the US, 10% in Europe and 8% in the developing 
world (Parkin et al., 2005). Beyond differences in outcomes worldwide, several studies 
have documented differences in incidences rates, treatment, and outcomes in the US 
between minorities and Whites.   
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Lung cancer disparities research 
For more than two decades healthcare providers and policy makers have known 
about racial disparities in the treatment and outcomes of lung cancer.  There is an 
established body of research that has demonstrated differences in access to 
chemotherapy, radiation, and surgical treatment of lung cancer (Gross, Smith, Wolf, & 
Anderson, 2008; Herrin, Wong, & Krumholz, 2005; Lathan, Neville, & Earle, 2006; 
Bach, Cramer, Warren, & Begg, 1999).  Other studies have found that higher levels of co 
morbidity, later stage diagnosis and poorer performance status among Black lung cancer 
patients contribute to poorer outcomes (Blackstock et al., 2006). These differences 
contribute to higher rates of morbidity and mortality for minority lung cancer patients. 
Prior to age 45, Blacks have a significantly lower risk of being diagnosed with 
lung cancer than White men (Karami, Young, & Henson, 2007). However, after age 45, 
differences in incidence, mortality, and survival rates between Black men and White men 
are dismal. Although there are significant differences in mortality rates between White 
and Black men, the lifetime risk for Black men to be diagnosed with and die from lung 
cancer is similar to White men. This is because Black men have other significant health 
burdens as they reach middle age, which causes earlier mortality. The lifetime risk of 
diagnosis for lung cancer is 7.86 for White men and 7.75 for Black men.  The lifetime 
risk of death due to lung cancer is 7.17 in White men and 6.99 in Black men. The median 
age at diagnosis of lung cancer in Black men is 66 years old, five years earlier than 
whites. Black men experience a significantly higher rate of age adjusted incidence of lung 
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cancer compared to White men.  28.3 more Black men per 100,000 are diagnosed with 
lung cancer than White men.  A similar difference exists in the age adjusted death rate. 
21.8 more Black men per 100,000 die from lung cancer than White men. It is worth 
noting that, although a similar disparity exists between Black and White women, it is far 
smaller at 2.1 more deaths per 100,000 Black women than White women. The most 
significant racial disparity in lung cancer is in the incidence, death, and five year survival 
rates per 100,000 patients. The incidence rate in Black men is 28.3 per 100,000 higher 
than in White men.  The death rate is 21.8 per 100,000 higher.  And, the five year 
survival rate is 3 patients per 100,000 lower (Jemal A, Siegel R, Ward E, et al, 2008). 
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Table 5 summarizes the racial disparities in outcomes for lung cancer patients. These 
statistics clearly illustrate that Blacks, men in particular, bear a disproportionate share of 
the lung cancer burden.   
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Table 5 
Racial Differences by Gender on Measures of Lung Cancer Morbidity and Mortality 
 
 Table 6 
White/Black difference in each measure 
 
 
The lack of minority enrollment in lung cancer clinical trials and under representation of 
minorities at NCI cancer centers may contribute to some of the existing disparities in lung 
cancer outcomes.  Lack of representation in lung cancer clinical trials may also be 
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contributing to limited information about the actual incidence and significance of racial 
differences in lung tumor molecular biology. Given the growing approach to personalized 
cancer care, in which the knowledge of tumor biology informs drug development 
research, under representation of patients from specific ethnicities or race in biomarker 
clinical trials research may be widening the gap in cancer outcomes.    
The reasons for differences in enrollment of ethnic and racial minorities are 
mutlifactorial.  Several studies illustrate the relationship between likelihood to enroll in 
clinical research and age, race, socioeconomic status, rural/suburban residence, proximity 
to comprehensive cancer centers, availability of transportation, comorbid conditions, type 
of cancer diagnosis, and religious/spiritual beliefs (Adams-Campbell et al., 2004, Advani, 
Goldstein, & Musen, 2002, Murthy, Krumholz, & Gross, 2004).  
More recent medical research illustrates that healthcare provider and market 
factors also influence enrollment in clinical research (Gross & Krumholz, 2005).  
Implications for lower minority enrollment in lung cancer clinical trials are best 
illustrated by an analysis of the knowledge about incidence of EGFR mutations in blacks.   
Clinical trials of EGFR mutations and EGFR TKIs 
The incidence rate of EGFR mutations in Blacks is derived from two studies 
(Leidner et al., 2009; Yang et al., 2005). These studies analyzed a total of 94 patients who 
self identified as Black. Both studies sought to confirm information that has generally 
become believed by thoracic oncologists, despite limited published evidence with small 
sample sizes, that EGFR mutation in Blacks is rare. Most Black patients that participated 
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in Yang’s study were from the University of Maryland Medical Center. One Black 
patient was from Mayo Clinic in Minnesota. All patients that participated in the trial by 
Leidner et al. (2009) were from University Hospitals Case Medical Center in Cleveland, 
Ohio. The incidence rate of EGFR mutations in the Yang study was 2.4% or 1 patient. 
Similarly, Leidner and colleagues reported 1 patient (2%) among their 53 Black patients 
tested positive for EGFR mutations. 
The limited published evidence about the incidence of EGFR mutations in Blacks 
prompted the author to conduct a systematic review to determine whether sufficient 
numbers of Black patients were included in these studies to establish evidence on 
incidence rate of EGFR mutations in Blacks. This review analyzed thirty six multi 
institutional domestic and international EGFR TKI clinical trials and retrospective 
molecular tissue studies which took place between 2001and 2010.    
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Table 7 lists the studies analyzed 
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Table 7 
Name of Clinical Trial, Compound, and Number of Patients 
 
Notes: Summarizes patients that participated in U.S. multisite EGFR TKI clinical trials 
Source: Author’s construction from systematic review of EGFR TKI clinical trials 
 
This review revealed that Blacks represented less than 3% and Hispanics 
represented less than 1% of patients of phase II and III studies. These results are 
demonstrated below. 
Trial Name
Year
Reported
Number of 
Patients
Compound
IDEAL-1 2003 210 Gefitinib
IDEAL-2 2003 221 Gefitinib
INTACT-1 2004 1093 Gefitinib
INTACT-2 2004 1037 Gefitinib
BR.21 2005 731 Erlotinib
SO126 2005 135 Gefitinib
TRIBUTE 2005 1059 Erlotinib
ISEL 2005 1692 Gefitinib
iTarget 2008 98 Gefitinib
INVITE 2008 196 Gefitinib
SO341 2008 81 Erlotinib
SWOG S0023 2008 571 Gefitinib
INTEREST 2008 1466 Gefitinib
SATURN 2010 889 Erlotinib
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Table 8 
Number of Studies Reporting Ethnicity/Race by Phase of Research 
 
Notes: Studies included in systematic review categorized by stage 
Source: Author’s construction 
 
Table 9 
Ethnicity and Race Reported of Patients in Phase II and III Studies  
 
Notes: Studies included in systematic review categorized by stage, ethnicity and race 
reported 
Source: Author’s construction 
 
Type of 
Study
# of
Studies
Race/
Ethnicity not 
reported
Reported 
only 
Whites 
& Asians
Reported 
Blacks
Phase I 4 4 0 0
Phase II 12 3 5 4
Phase III 9 0 2 7
Molecular 12 3 6 3
Total/% 37 27% 35% 38%
* Several molecular studies were conducted on phase I and II trials already presented 
in table.
Phase II Phase III Total %
White 811 6679 7490 76%
Black 14 233 247 3%
Asian 2 1002 1004 10%
Hispanic 154 65 219 2%
AI/AN 0 4 4 0%
Other 98 804 902 9%
Total 1079 8788 9867 100%
Reported Race/Ethnicity in 
Phase II & III studies of EGFR/TKIs
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Many studies analyzed were conducted after the 2003, 2004, and 2005 regulatory 
approval and commercialization of EGFR TKIs and the EGFR assay. Yet, this systematic 
review of EGFR TKI studies clearly indicated barriers exist in access to these important 
advances in diagnosis and treatment among minority populations.  No studies to date 
have analyzed whether institutional and regional differences in the diffusion of lung 
tumor genotyping technologies contributes to a lack of access and hence a lack of 
understanding about lung tumor biology in minority populations.  This background and 
summary clearly demonstrate the urgency of understanding barriers to the diffusion and 
utilization of molecular diagnostic technologies for minority populations. These 
technologies have become an important tool in the discovery of genetic alterations that 
lead to carcinogenic pathways in lung cancer. These studies are also a tool in the 
development of new treatments.  
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CHAPTER 3 
Methods 
This is a cross sectional, retrospective, observational study, which uses secondary 
data analysis research methods to analyze seven datasets which were merged into two 
separate analytic files. One analytic file has institutions as the unit of analysis. The other 
analytic file has county as the unit of analysis. Of the datasets merged, one was 
proprietary. It contained the key dependent variable, number of orders placed for the 
EGFR assay from Genzyme Genetics for the calendar year 2010. The independent 
variables analyzed were obtained from seven publically available datasets which were 
merged with the EGFR data warehouse to create two analytic files.  The unit of 
observation in the principal analytic file was acute care hospitals and institutions in the 
US that ordered the EGFR assay.  The unit of observation in the second analytic file, a 
contracted version of the first, was counties in the US in which acute care hospitals are 
located. The study involved less than minimal risk to human subjects because it used 
existing administrative billing data that was de-identified. A description and source for 
the public datasets is listed in Table 11.  A flowchart illustrating the process for joining 
these datasets is provided below.  
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Figure 5 
Flowchart of Process for Linking Datasets to Create Analytic File 
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Description of proprietary dataset 
On April 15, 2011, Genzyme Genetics, the company which owned the rights to 
distribute the EGFR assay, extracted all the orders for the EGFR assay in US territories 
for the calendar year 2010 from their data warehouse. This dataset was emailed to the 
researcher on April 22, 2011. It included variables about the name, city, state, zip code, 
and number of units sold to each hospital or lab requesting EGFR analysis. It also 
included the gender and payer of the patient. According to Genzyme Genetics, this data 
set represents approximately 98% of the EGFR assays conducted on behalf of community 
hospitals within the United States. However, this dataset is not a comprehensive 
representation of EGFR assays conducted at NCI CCs.  
NCI CCs, particularly those that are characterized as comprehensive centers, often 
have their own CLIA certified labs and the capability to conduct EGFR assay alone or as 
part of a multiplex of mutations sequenced independent of Genzyme Genetics.  The 
researcher contacted a few NCI CCs to corroborate this information. Although the EGFR 
assay warehouse does not represent a comprehensive picture of NCI CC utilization, there 
is some information about the NCI CCs.  For example, Moffit Cancer Center in Tampa, 
Florida and Mayo Cancer Center in Rochester, Minnesota have contracts with Genzyme 
Genetics to conduct EGFR analysis at a special contracted rate. Therefore, information 
about these two centers is likely complete.  Additionally, there were a large number of 
tests ordered from Johns Hopkins and Duke University, which suggest that these 
institutions are also sending all their requests for an EGFR assay to Genzyme Genetics, 
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rather than processing these within its own lab. Table 10 summarizes the original data 
Genzyme Genetics provided characterized by type of institution. 
Table 10 
 
 
    
In the original data file that Genzyme Genetics sent, there were 7,957 units of EGFR 
assay ordered as part of 7,804 orders.  Orders from institutions that resided outside the 
continental US were removed from the data set leaving 7955 tests ordered from 742 
different institutions. In total, there were 1019 tests ordered from 27 NCI CCs. For the 
purpose of consistency, all tests ordered from NCI CCs were removed from the dataset so 
that this information was not included in the analysis.  
Description of public datasets 
The variables included in the public data sets are represented either at the 
institutional level (CMS/NCI provider of service file) or at the county level. Each of these 
datasets and the variables of interest are described in Table 11. There are 3,142 counties, 
county equivalents, or independent cities in the US.  Each county is assigned a state and 
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county level  FIPS code.  Combined these make a unique identifier for each county.  
Table 11 
Public Use Data Sets  
Source Description 
Census Bureau 
Population Data  
This dataset was downloaded from the website: 
http://www.census.gov/population/www/popdata.html. It contains 
county level population characteristics (size, ethnicity/race, 
income, education, number of hospital beds, physicians, and 
community hospitals). 
Census Bureau 1999 
ZIP Code file  
This dataset was downloaded from the website: 
http://www.census.gov/geo/www/tiger/zip1999.html. It contains a 
list of the United States’ zip codes, latitude, longitude, city, 
county and state federal information processing standards codes 
(FIPS). FIPS codes uniquely identify geographic areas.  State-
level FIPS codes have two digits, county-level FIPS codes have 
three digits and are unique within each state. 
National Institute of 
Standards and 
Technology (NIST)  
This dataset was obtained from the following website: 
http://www.itl.nist.gov/fipspubs/co-codes/states.txt.  
It provides a list of county and state level FIPS codes. 
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The National Program of 
Cancer Registries (NPCR) 
and Centers for Disease 
Control and Prevention 
(CDC) State Cancer 
Profiles  
This dataset was obtained from the website: 
http://statecancerprofiles.cancer.gov/incidencerates/index.php. It 
provides state and county level lung cancer incidence through 
2008.   
2009 Center for Medicare 
and Medicaid Services 
(CMS) Provider of 
Services (POS) file 
This dataset was obtained from CMS. Institutions that bill CMS 
for patients are required to submit an annual survey that provides 
information about the institution’s ownership and operational 
characteristics. Each institution that provides Medicare patients 
with healthcare services is assigned a unique identifying number 
called the Oscar number. 
2010 National Cancer 
Institute (NCI) POS file 
NCI enhanced the CMS POS file with information about 
institutional participating as a designated cancer center or in NCI 
sponsored cooperative. The researcher paid a fee of $150, the cost 
to develop an unencrypted version of the file that revealed the 
institution’s Medicare Oscar number so that the researcher could 
link the NCI variables with the CMS POS file directly. 
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U.S. Department of 
Agriculture division 
of Economic 
Research Services 
(USDA ERS) 
This dataset was downloaded from the website: 
http://www.ers.usda.gov/Data/TypologyCodes/. It’s a 12 code 
classification system based on county rural/urban and 
metropolitan status. 1 and 2 are assigned to small and large 
metropolitan areas based on population of 1million residents.  
Creating the analytical file 
All patient identifiers were removed from the dataset Genzyme Genetics 
provided.  However, the name, address, and zip code of each institution that ordered the 
EGFR assay on behalf of patients were provided.  The researcher aggregated these 
individual patient orders to the institutional level then obtained the institution’s Oscar 
identification number from the CMS POS file.  The Census Bureau zip code file was 
merged with the EGFR data warehouse to assign a FIPS number to each institution.  
Once the acute care hospitals in the EGFR dataset were assigned the correct Oscar 
number, the NCI POS file and CMS POS files were merged with the EGFR assay data 
warehouse.  Then, using the FIPS number of each institution, the publicly available data 
sets from the Census, National Program of Cancer Registries and the Centers for Disease 
Control (CDC) were merged with the EGFR data warehouse, to create the final analytic 
file. 
Refining the Public Data Sets 
Datasets needed to be sorted and condensed.    
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Table 12 summarizes those changes.    
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Table 12 
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Counties without acute care hospitals were removed from the final county 
analytic files.  Hospitals that were unlikely to be treating lung cancer patients were 
removed.  These included psychiatric, Christian Science and long term care facilities.  
Analysis was limited to diffusion of the EGFR assay within continental US. Therefore 
institutions operating outside the US were removed.   
The most time consuming process of refining the data was culling out duplicates 
or inactive hospitals from the CMS/NCI POS files.  Most research that analyzes the 
relationship between quality of care and institutional characteristics licenses the 
American Hospital Association (AHA) database for approximately $5000.  The cost to 
license this was beyond the resources available to the researcher. Therefore it required 
significant investment of time identifying and deleting dated, duplicated, or closed 
facilities that continue to have an active provider (Oscar) numbers in the CMS database. 
It should also be noted that the AHA database does not include the required variables 
from the NCI. Although NCI dataset is public, most researchers use it through SEER and 
the institution’s identification is encrypted.   
Effort was invested in matching the name and address of the institution as listed in 
the Genzyme Genetics Warehouse to their names in the CMS/NCI POS file. In some 
cases it was exactly the same name.  In other cases one dataset used the university name 
while the other used the hospital name.  There were no cases where the matching was not 
apparent.  However, in several observations, independent pathology laboratories were 
operating within, or on behalf of, an acute care hospital.  When this relationship could be 
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conclusively established, the order was assigned to that acute care hospital. However, 
there were 108 institutions (60 pathology labs and 47 physician offices or outpatient 
cancer centers) that were included in the analytic file but whose affiliation could not be 
directly linked to an acute care hospital.  These observations had institutional 
characteristics listed as missing and will be dropped from any regressions that use 
institutional capabilities, or participation in NCI cooperative group variables. A similar 
dynamic existed with the institutions owned by the Federal government.  Federal 
institutions are exempt from filing the requisite updates to the CMS POS file.  Yet, some 
of the Veterans Health Administration hospitals (VA) participate in NCI cooperative 
groups and see Medicare patients.  Therefore, in some VA observations, the institutional 
characteristics are listed whereas in other observations these are missing. The researcher 
could identify no timely and accurate way to impute the missing data.  Therefore, for 
those observations that are missing institutional characteristics, the observations will be 
dropped from any regressions that use these variables. However, these observations are 
included in the regional analysis. These limitations in the dataset will be discussed in the 
results and conclusions. 
In the CDC/NPCR datasets, data on annual number of lung cancer cases and lung 
cancer incidence are based on the year 2008.  These data were submitted via the states 
cancer registries to the CDC/NPCR in January 2010 and made available to the public and 
researchers in August 2011. These data was for the most part comprehensive and 
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complete.  However, there were some counties in which data was suppressed.   The basis 
for imputing data for these counties is discussed below. 
For all counties in the states of Kansas and Minnesota, state policy prohibits 
releasing data outside the county.  For counties in Kansas and Minnesota, the average 
annual lung cancer cases and incidence for male and female from years 2002 – 2006 were 
provided on state web sites.   From these numbers, total annual number of cases and 
incidence per county were imputed using the same age and population adjustment 
methodology SEER uses.  
In 221 counties that had fewer than 3 lung cancer cases per year, data was 
suppressed due to confidentiality. For these counties the number 1 was imputed.  For 
these same counties, if the average annual incidence was below 16, these numbers were 
suppressed due to confidentiality.  In these 221 counties, I assumed the lung cancer cases 
on average were 8. For 62 counties and parishes in Alabama, Mississippi, Louisiana, and 
Texas, data was suppressed due to population shifts that resulted after hurricane Katrina.  
The average annual number of cases in these counties was imputed from the year prior to 
hurricane Katrina. 
Once the final analytic file was created, several additional derivative variables 
were calculated and generated.  The county age, education, and income data was 
originally included as a continuous variable, percent of the county population.  However, 
when incorporating these variables into stage 1 and stage 2 logistic regression models, the 
collinearity between these variables caused the model to fail.  Transforming these 
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variables to a dichotomous variable based on the mean, allowed the model to run. The 
solution to this was to change it to a  when that data   These include: 
Table 13 
Variables generated from original datasets 
Variables created for analysis of NCI CC in county Coded 
NCI Institution is an NCI CC 0/1 
Ed_BS_Mean County has above the mean (17%) of residents 
with BS degree 
0/1 
Ed_BS_45% County has more than 45% of residents with 
BS degree 
0/1 
Income_75K_Mean County has above the mean (14%) of residents 
with Income greater than $75, 000 
0/1 
Age_under_45_Mean County has above the mean (59%) of residents 
with Income greater than $75, 000 
0/1 
Variables created for institutional analysis - institutional 
characteristics and likelihood of ordering EGFR assay 
Coded 
Chemo, Pet, 
Cardiothoracic surgery, 
Med school 
All variables about institutional 
capability, were originally coded as 0 - 4. 
0 - no capability; 1,2,3 provided by staff, 
agreement, or combination recoded as 1 
0/1 
Coop Institution participated in any NCI 
clinical research group 
0/1 
NonCoop Non Coop 0/1 
Recipient Non NCI CC 0/1 
Distance_NCI Calculated as miles between Recipient 
hospitals (Non NCI CCs) and NCI CCs 
0-1921 
Closest_NCI NCI CC for which the Distance_NCI is 
calculated 
Name of 
hospital 
Num_EGFR Number of EGFR assays institution 
ordered 
0-168 
Inst_EGFR Whether institution ordered even 1 
EGFR assay 
0/1 
EGFR_rate Number of EGFR assays ordered in 
county/annual lung cancer cases 
0-.9 
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Variables created for regional analysis of EGFR rate and county 
characteristics 
Coded  
Ids_in_FIPS Hospitals in county   
Med_in_FIPS Hospitals with a medical school affiliation in 
county 
0-36  
Coop_in_FIPS Hospitals that participate in NCI clinical 
research group in county 
0-24  
Chemo, MRI, Pet,  
Cardiothoracic 
surgery_in_FIPS 
Hospitals with a Chemo, MRI, Pet Scan, 
Surgery capabilities in county 
0-24  
NCI_in_FIPS NCI CC in county 0/1  
EGFR_FIPS Number of EGFR assays ordered in county 0-249  
EGFR_Inst_FIPS Number of institutions ordering EGFR assay in 
county 
0-16  
    
Statistical Methods 
Descriptive statistics will be used to summarize the variables within the three 
equations of the conceptual model. Univariate analysis will be used to summarize the 
categories of institutions ordering the EGFR assay and the characteristics of the hospitals 
and counties. Bivariate analysis will be used to summarize the location of the NCI CCs, 
institutional and county characteristics by status of ordering the EGFR assay.   
Generalized linear models will be used for testing hypotheses.  Logistic regression 
will be used to test equations 1 and 2 of the model, which is the likelihood a county has 
an AMC that obtains NCI designation and the likelihood an institution orders an EGFR 
assay.  Multivariate regression will be used to test the contribution each independent 
variable makes toward predicting the dependent variables of equation 3, EGFR rate. 
Logistic and multiple regression will determine whether the independent variables are 
having the hypothesized effect based upon whether the odds ratios are different than 1 or 
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the coefficients are greater than 0. Both the logistic and multivariate regressions will be 
conducted by manually stepping in each independent variable to analyze the correlation 
between the independent variables and the subsequent impact on the odds ratios or 
coefficients.  
Methodological challenges 
There were several challenges working with these datasets.  A major drawback to 
this dataset is that it lacks patient level data.  As has been demonstrated in Chapters 2 and 
3, the driving motivation behind this study was to determine whether racial disparities in 
access to the EGFR assay contribute to lack of knowledge about the incidence of EGFR 
mutations in Blacks.  It was hoped that regional analysis of diffusion might explain the 
hypothesized racial difference in access to the EGFR assay. Yet, for two reasons, regional 
analysis failed to establish a racial disparity in access to the EGFR assay. The fact that 
NCI CCs locate in metropolitan counties which have dense Black populations suggests 
that there are not regional barriers to access for the EGFR assay. However, regional 
analysis fails to consider the age of the minority populations in communities close to the 
NCI CC. Minority populations living close to NCI CCs tend to be younger than the 
population of patients who get cancer, therefore they may not be seeking care at the NCI 
CCs. Further, there are a large percentage of whites living in rural, non metro counties 
that are not being provided access to the EGFR assay.  Therefore, even when the patient 
level data is analyzed, the hypothesized racial disparity may not be significant given the 
equivalent disparities among White populations. Without the patient level data from the 
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Medicare claims files, it is not possible to prove that Black patients are not accessing the 
assays that the NCI CCs are conducting. Therefore, this dataset does not allow that 
question of racial disparities to be analyzed.  
The lack of comprehensive data on NCI CC testing is also a drawback in the 
dataset. Table 3 suggests that the number of EGFR assays conducted by NCI CCs may 
exceed the number of assays conducted nationally. The absence of this data from the 
analysis weakens the explanatory power of any model to determine regional causes that 
drive the EGFR diffusion rate (equation 3). If this data were included, there would likely 
be very high utilization rates in counties which have an NCI CC, or those in close 
proximity to these counties, with low or zero utilization in distant counties.  
There are several other factors that may both strengthen and weaken the 
explanatory effect of the model.  503 counties in the US have no acute care hospitals 
located within their boundaries.  These counties were removed from the dataset on the 
premise that patients would not have access to the required medical procedure to obtain 
tumor tissue. However, some of these patients are likely traveling to other counties to 
obtain care.  It is difficult to capture the impact border crossing has on the regional EGFR 
rate without having access to the patient data.  The challenge that border crossing poses 
to regional analysis of healthcare utilization applies even when there is are acute care 
facilities located within the counties. Cancer patients may be more likely to travel to seek 
care in specialty hospitals. This may have been one of the factors contributing to 4 
counties within the US having utilization rates above the number of annual lung cases for 
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that county. If this happened with other counties, this may be giving greater weight to the 
sociodemographic variables of the counties in which patients are seeking care and 
weaken the effect of the distance to NCI CC variable.  
Logistic regression tends to systematically overestimate odds ratios or beta 
coefficients when the sample size is less than about 500 (Nemes et. al, 2009). Although 
the sample size of both the institutions and counties is greater than 500, the outcome of 
counties ordering the EGFR assay is only 379 of the 2,359 counties analyzed. Similarly, 
once NCI CCs and outliers were removed from the dataset, there were only 708 
institutions of the 7007 institutions analyzed.  This may result in an overestimation of the 
odds ratios and beta coefficients.  Therefore, sensitivity testing will be conducted on the 
model and it will be run in several different ways, eliminating counties that have no acute 
care facilities from the analysis as well as running the regression only on those counties 
which have at least 1 institution that has ordered an EGFR assay.  
These methodological problems underscore the importance of conducting an 
analysis of patient access to lung tumor genotyping using the Medicare claims data on 
individual patients. The vast majority of lung cancer patients are Medicare patients. 
Therefore, analysis of the 331,000 lung cancer patients Medicare claims file will provide 
a comprehensive analysis of quality of lung cancer care and variable driving access to 
personalized cancer care.  
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CHAPTER 4 
Equation 1 Results 
The first step in the conceptual model was to determine the likelihood a county has a 
hospital that obtained NCI designation.    
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Table 14 is an analysis of the county typology, as defined the US Department of 
Agriculture Economic Research Services (USDA ERS), with the location of NCI CCs, 
acute care and critical access hospitals, institutions ordering the EGFR assay, number of 
assays ordered, percentage of the US population, percentage that is black, and lung 
cancer incidence.  
Sixty of the sixty two NCI CCs are located within large or small metropolitan 
counties which also have a higher percentage of residents that self identify as Black. 
However, to test this when considering the other independent variables, a logistic 
regression is required.  
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Table 14 
 
Notes: Ctys is counties; Hosp. is hospitals; CAH is critical access hospital; Ann Inc. LC 
is annual incidences of lung cancer per 100,000 people. 
Source: Author’s construction.  
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Table 15 illustrates the results of the logistic regression analyzing the likelihood a 
county has a hospital which obtained NCI designation. It illustrates the progressive effect 
each independent variable added to the model has on the odds ratios of the other 
variables. The chi-square of .0000 indicates that there is essentially no possibility of the 
null hypothesis that the independent variables proposed, operating together, are unrelated 
to the dependent variable, location of hospitals which obtain NCI designation within a 
county 
The first variable stepped into the model was number of hospitals in the county 
affiliated with an AMC.  This was chosen because, although patient care is an important 
component of an NCI CC, generating research funding through collaboration with 
academic medical institutions is likely a critical factor to obtain NCI designation.  This 
model illustrates that hypothesis 1 of stage 1 is supported; even when all other 
independent variables are added to the model, concentration of hospitals associated with 
a academic institutions is a strong predictor of a county having an NCI CC located within 
its bounds. 
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Table 15 
Logistic regression of likelihood a county has a hospital which obtained NCI designation 
 
 
 
Metropolitan county is a significant factor in the model when you control for race, 
education, and income.  However, once you control for age, metropolitan county is no 
longer significant because the model has essentially mimicked all the sociodemographic 
characteristics associated with a metropolitan county.  Similarly, when you control for 
metropolitan county, the percentage of residents that self identify as Black is not 
significant. Therefore, hypotheses 2 and 3 of the equation 1 of the conceptual model are 
not supported. Hypotheses 4, 5, and 6 are accepted: When the population has more than 
45% of its residents with at least a bachelor degree, more than 14% of it’s population has 
income over $75,000, and more than 59% of its population is under age 45, the county is 
21.91 times more likely to have a hospital that obtains NCI designation as a cancer 
center.  
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 Census socio demographic variables are continuous variables between 0-100 
percent. However, these variables are highly intercorrelated. When the logistic regression 
analysis was conducted, the model became unstable and unreasonable odds ratios were 
generated.  Therefore, these variables were recoded to 0/1 variables to run the model. The 
0/1 transformation works because it limits the number of cells in the model. These 
variables were constructed by obtaining the mean level of the population that had the 
specific characteristic. The counties which had greater than the mean were coded as 1. 
For example, for all the counties analyzed, 14% of the population had Income over 
$75,000. Therefore, this variable was initially recoded as 0/1 with a 1 representing that 
the county with more than 14% of its population having income greater than $75,000. 
The same process was applied to age.   
I handled the transformation of the education variable differently. Initially, I 
transformed it to a 0/1 variable based on the mean of 17%.  However, the odds ratio 
remained very high which indicated designation of an NCI cancer center was highly 
sensitive to education level. To test the sensitivity of this variable, I increased it to as high 
as 45% of the population.  At this level, BS education maintained a statistically 
significant odds ratio. Therefore, in the NCI analysis, counties with at least 45% of its 
population with a BS level education, are indicated with a 1.  These counties are 7 times 
more likely to have an NCI CC located within it. 
There is some debate about which variable came first. Did high level of education 
in the county increase the likelihood that an academic medical center obtained NCI 
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designation or does having an NCI designated cancer center in the county increase the 
level of education? It is not possible to test it within this study.  However, it is 
worthwhile testing the sensitivity of the education variable.   
The final variables that have statistically significant odds ratios are highlighted 
with a single asterisk for a p-value of less than .05 and a double asterisk for a p-value less 
than .10. When all the variables are included, model 6, the odds ratios for each significant 
independent variable can be interpreted in the following manner: For each additional 
hospital that is affiliated with an AMC, holding all other variables constant, that county 
has a 56% greater chance of having a hospital that obtained NCI designation. If the 
county has 45% or more of its population with at least a bachelor degree education, 
holding all other variables constant, it is 7 times more likely to have a hospital that 
obtained NCI designation. If the county has more than 14% of its population with income 
above $75,000, holding all other variables constant, it is 4.12 times more likely to have a 
hospital that obtained NCI designation. If the county has 59% or more of its population 
under age 45 years, holding all other variables constant, it is 4.12 times more likely to 
have a hospital that obtained NCI designation. 
Equation 2 Results 
Equation 2 tests the likelihood an institution orders the EGFR assay. Of acute care 
hospitals in the US, 12% (n=592) ordered the EGFR assay. In 49 counties with an NCI 
designated cancer center (NCI CC), 19% of hospitals ordered the assay, whereas only 
11% of hospitals in non NCI counties ordered the assay.   
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Table 14 illustrates that, as with the NCI CCs, 89% of hospitals ordering the 
EGFR assay were located within metropolitan counties.  These hospitals accounted for 
93% of total EGFR assays ordered.  83% of the US population lives within these 
counties.  However, within the large metropolitan counties, the annual incidence of lung 
cancer is lower than the national mean of 68.75 cases per 100,000 or 158,799 annual 
cases of lung cancer.  There are very few assays ordered in non metropolitan counties, 
454 or 7% of total assays.  Further, there are 42,550 annual cases of lung cancer in these 
counties (21% of the lung cancer population), who appear to have little access to the 
EGFR assay.  Table 14 strongly indicates that the disparity that exists in access to the 
EGFR assay is location within a rural county. 
Table 16 summarizes the type of facility, mean rates and distribution of EGFR 
assays ordered. The mean number of assays ordered from the laboratories and physician 
offices should be interpreted with caution. The mean for this type of facility is overstated 
because it does not include all the laboratories and physician offices in the country that 
did not order the test.  However, all acute care, critical access, and federal hospitals are 
included in the analysis. Therefore, the mean for these types of facilities is accurate.  
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Table 16 
 
Type of Facility and Mean Rates and Distribution of EGFR Assays 
Description Coded Obs Mean SD Min Max 
Identifies 
whether order 
came from 
hospital listed 
in CMS/NCI 
Provider of 
Service (POS) 
dataset. 
0 – Hospital 3484 1.74 7.48 0 168 
11 - Critical Access 1296 0.00 0.08 0 2 
1- Lab 60 8.67 13.16 1 55 
2 – Outpatient 48 4.25 6.60 1 29 
3 – VA 161 0.36 1.87 0 16 
4- Military 155 0.23 1.79 0 18 
5 - Other Fed 22 0.00 0.00 0 0 
6 – USPH 22 0.00 0.00 0 0 
Notes: Only laboratories that ordered the assay are included in data. 
Source: Author's construction 
 
Table 17 summarizes the descriptive statistics of hospital and regional characteristics by 
status of ordering the EGFR assay. It illustrates that there are 57% (2704) hospitals 
located within metropolitan counties. Yet, 88% of hospitals that ordered the assay are in 
metropolitan counties.  56% (2683) of hospitals are in counties with education at BS level 
above the mean. Yet, 84% of hospitals ordering the EGFR assay are in counties with 
bachelor degree education level above the mean.   24% (1166) of hospitals have an 
affiliation with an academic medical center. Yet, 48% of hospitals ordering the EGFR 
assay are affiliated with an academic medical center. A similar pattern exists with 
chemotherapy and PET scan services and participation in an NCI cooperative. While only 
25% of hospitals in the database offered cardiothoracic surgery, 56% of the institutions 
ordering the EGFR assay offered cardiothoracic surgery compared to 21% of institutions 
that did not order the assay.  Notice that only 2 of the 1295 Critical Access hospitals 
ordered the EGFR assay.    
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Table 17 
 
 The significant difference in means between hospitals that participated in NCI 
cooperative clinical research groups encouraged me to conduct a separate analysis on 
each of the cooperative groups to determine whether cooperative groups that participated 
in EGFR TKI clinical trials were also more likely to order the assay.  
 
Table 18 illustrates the descriptive statistics of NCI cooperative group 
membership by status of ordering the EGFR assay. NSABP, a surgical clinical research 
group, had the most number of hospitals participating in the cooperative group. 20% of 
hospitals that ordered the EGFR assay belonged to NSABP. 15% or 88 hospitals that 
ordered the assay belong to ECOG.  This table illustrates that proportionally, the highest 
percentage of hospitals ordering the EGFR assay, participated in ECOG (32% of 
hospitals participating in ECOG ordered the assay), ACOSOG and CALBG had 35% of 
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its members order the EGFR assay. These cooperative groups were also likely active 
participants in EGFR TKI clinical trials. 
Table 18 
 
Although the dependent variable in equation 2 is the hospital, regional 
characteristics in which the hospital is located are used as independent variables in this 
equation. Therefore, it is helpful to understand the descriptive statistics of these regional 
variables. Table 19 illustrates that there are approximately 2 (1.95) hospitals per county.  
However, many counties have hospitals which are not affiliated with a medical school, do 
not offer PET scan or cardiothoracic surgery, and do not participate in NCI cooperative 
groups. The average distance hospitals are from an NCI CC is 137.66 miles. Yet, there 
are some counties which have hospitals that are 1952.6 miles away from an NCI CC.  
The average annual lung cancer cases in counties are 76.31 in 2008. The average 
annual incidence of lung cancer in the counties is 70.24 per 100,000 people in 2008. In 
counties with acute care hospitals, 17% of the population has education at least at the 
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bachelor degree level. 59% of the population is under age 45. 14% of the population has 
income above $75,000. 9% of the population is Black. 35% of the counties are 
metropolitan. 
Table 19 
 
 
 
Notes: Calculated based on counties with acute care hospitals 
Source: Author’s construction 
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Error! Reference source not found. illustrates the logistic regression model. 
ach variable was stepped into the equation manually to demonstrate the correlation 
between these variables and the subsequent effect on the dependent model. In model 1, 
distance to the NCI CC was the first variable stepped in because the central hypothesis 
was diffusion of the EGFR assay emanates from the NCI cancer centers. The odds rate 
.991 was generated with a p-value of .00 indicating that for each mile a hospital is away 
from an NCI, the lower the likelihood it will order the EGFR assay. Next, affiliation with 
a medical school was stepped in because I hypothesized that these types of hospitals 
would be early adopters of innovations.  Model 2 illustrates that hospitals affiliated with a 
medical school are 3.12 times more likely to order the EGFR assay, even when 
controlling for distance to the NCI CC.  In model 3, participating in a NCI clinical 
research cooperative group (Coops) was the third variable stepped in because these 
hospitals are more likely to have been exposed to the EGFR assay through participation 
in an EGFR TKI clinical trial.  Model 3 illustrates that Coops are 3.13 more likely to 
order the EGFR assay.  However, by stepping in this variable, it decreases the impact 
affiliating with a medical school has on the dependent variable because many Coops are 
also likely to be affiliated with a medical school.  In model 4, PET scan services was 
stepped in.  Although PET scans are not widely used in treatment of lung cancer, this 
variable is a proxy for hospitals that are early adopters of technology. Hospitals that offer 
PET Scan services are 1.89 times more likely to order an EGFR assay. 
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Table 20 
 
Notes: Most variables were significant therefore p-value of greater than .05 have an asterisk. 
Source: Author’s construction 
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PET Scan services also decreased the impact medical school affiliation and participation 
in a cooperative group had but did not change the influence distance had on the 
likelihood of ordering the EGFR assay.  Model 5 stepped in the variable cardiothoracic 
surgery services.  Hospitals that offer cardiothoracic surgery are most likely to conduct 
lung cancer surgery and therefore likely to have more lung tumor tissue available for 
conducting the EGFR assay.  This hypothesis was supported. Hospitals that offer 
cardiothoracic surgery are 2.61 times more likely to order the assay.  However, there is 
clearly some correlations between these hospital characteristics because the influence of 
medical school affiliation, participating in an NCI cooperative group, and offering PET 
scan services decreases when cardiothoracic surgery is added.  All hospital characteristics 
except chemotherapy services remain significant predictors of ordering the EGFR assay.  
Model 6 steps in inpatient chemotherapy services.  This variable is not statistically 
significant.  Although inpatient chemotherapy services is an indicator of offering 
advanced cancer care services, the effect of this variable is likely being captured by the 
previous characteristics. Hospitals that affiliate with a medical school, participate in NCI 
cooperative groups, offer PET scan and cardiothoracic surgery, are also likely to offer 
chemotherapy services. In model 7, I stepped in the regional variable of location within a 
metropolitan county.  As illustrated, when controlling for all other variables, location 
within a metropolitan county is a significant predictor of ordering the EGFR assay.  
Model 8 steps in the education level of the county. When controlling for distance to the 
NCI CC, all the institutional characteristics, and location within a metropolitan county, 
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hospitals located within counties that have more than 17% of their population educated at 
least the bachelor’s degree level, are more likely to order the EGFR assay. Model 9 
illustrates that the percentage of Blacks within a county is not a significant predictor of 
whether the hospital orders the EGFR assay.  As was illustrated in equation 1, hospitals 
that order the EGFR assay may be located in urban metropolitan communities that have a 
high minority population. Therefore, hypothesis 7 is not supported.  Model 10 tests 
hypothesis 9, whether, controlling for distance, institutional characteristics, and other 
regional characteristics, a hospital located in a high income county is more likely to order 
the EGFR assay.  This hypothesis is supported. Controlling for all other variables, 
hospitals located in counties that have more than 14% of its population with income 
above $75,000 are 1.46 times more likely to order the EGFR assay.  
 Model 11 stepped in the annual number of lung cancer cases in the county.  In an 
equitable and rational healthcare system, this variable would be the biggest causative 
factor driving both the number of EGFR assays ordered as well as the number of 
hospitals ordering the assay.  However, as model 11 illustrates, this is not a statistically 
significant factor in whether a hospital orders the EGFR assay.  
Other than hypotheses 1 and 7, all hypotheses in equation 2 are supported. Neither 
number of lung cancer cases or percentage of Blacks living in a county had a statistically 
significant effect on whether a hospital ordered the EGFR assay.   
Hospital and regional characteristics had the hypothesized effect on likelihood a 
hospital would order the EGFR assay. Significant institutional predictors of ordering the 
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assay included: Participation in an NCI clinical research cooperative group (odds ratio 
[OR], 2.06, 95% CI 1.66 to 2.55), Cardiothoracic Surgery (OR, 1.90; 95% CI, 1.52 to 
2.37), PET Scan services (OR, 1.44, CI, 1.07 to 1.94), and affiliation with academic 
medical center (OR, 1.48; 95% CI, 1.20 to 1.83). Inpatient chemotherapy services were 
not statistically significant once all other institutional characteristics were stepped in. 
Significant regional predictors included: metropolitan county (OR, 2.08; 95% CI, 1.48 to 
2.91), education above the mean (OR, 1.46; 95% CI, 1.09 to 1.96), and income above the 
mean (OR, 1.46; 95% CI, 1.09 to 1.96). Negative predictors were distance from an NCI 
CC (OR, .996, 95% CI, .995 to .998), a 34% decrease in likelihood for every 100 miles 
further from an NCI CC. 
It is worth discussing hypothesis 5, distance to a comprehensive cancer center, in 
greater depth. The hypothesis was that distance between the hospital and an NCI CC will 
have an inverse relationship to the likelihood the institution ordered the EGFR assay. 
When this variable is initially stepped in, the odds ratio is lower than 1 and the p value is 
statistically significant.  However, once other variables are stepped in, the odds ration 
gets closer and closer to 1 yet remains statistically significant. This is explained by the 
fact that distance is a continuous variable measured as each mile the hospital is from the 
NCI CC.  With the exception of percentage Black, all other variables are measured as 
categorical 0/1 variables.  
The model was rerun in logit to obtain a coefficient for distance rather than an 
odds ratio.  The logit coefficient generated was -.00411 when the model was run on 
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institutions in non-NCI counties. I multiplied this by 100 miles and exponentiated which 
gave us a the value of .663. For every 100 miles further from an NCI CC, the likelihood 
of a hospital ordering the EGFR assay decreases by 34%. When hospitals in all counties 
were analyzed,for every 100 miles further from an NCI CC, the likelihood of ordering an 
EGFR assay decreases by 24%. This variable may have a non linear relationship with the 
dependent variable.    
Sensitivity Testing of Equation 2 Results 
In the methods section, there was some discussion about the possibility that the 
strength of the odds ratios may be overestimated given the low number of institutions 
ordering the EGFR assay and the limited number of counties in which these institutions 
operate. The sensitivity of the model was tested in a number of different ways. Table 21 
illustrates that when characteristics of just the 1662 hospitals located within the 383 
counties in which at least one hospital ordered an EGFR assay, the variables that remain 
significant are: participation in an NCI cooperative group and offering cardiothoracic 
surgery. Distance to a comprehensive cancer center and inpatient chemotherapy services 
are significant at a p-value of .10. In this analysis, annual lung cancer cases become a 
significant negative predictor of ordering the assay. When rounded, the odds ratio and 
confidence intervals become 1. The regional variables are not included because by 
limiting the analysis to hospitals in the 383 EGFR counties, the effects of education, 
income, and metropolitan county are captured within the EGFR county constraint. 
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Table 21 
 
Notes: Fewer variables were significant therefore p-value of less than .05 have an  
asterisk. 
Source: Author’s construction 
 
Another method of testing the sensitivity of the institutional characteristic and distance 
variables is to conduct an analysis of hospitals located outside NCI counties compared to 
within NCI counties. Tables 22 and 23 are the logistic regression models conducted by 
whether hospitals are located within NCI counties. All but 2 NCI CCs are located within 
metropolitan counties, therefore the regional variables were excluded from table 23 but 
included in table 22. As illustrated in table 22, there are 4,179 hospitals located non-NCI 
counties. All variables except percent Black and inpatient chemotherapy were statistically   
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Table 22 
 
Notes: Most variables were significant therefore p-value of greater than .05 have an  
asterisk. 
Source: Author’s construction 
 
significant in this model which suggests that, even with all the zeros in the analysis, the 
model is somewhat robust.   
Table 23 limits the analysis to the 538 hospitals located within 49 NCI counties. 
This analysis illustrates the strength of the variables participating in an NCI clinical 
research cooperative and offering cardiothoracic surgery.  The statistically significant 
odds ratios for the various models are compared in Table 24. While the regional variables 
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Table 23 
 
 
Notes: P-value of less than .05 have an asterisk. 
Source: Author’s construction 
 
would likely still be statistically significant, it is not possible to measure that when the 
analysis is restricted to EGFR and NCI counties because these are by default 
metropolitan counties, often with higher education and income levels. 
 Table 24 illustrates that when the analysis is restricted to a very select number of 
hospitals in NCI counties, the most significant predictor of whether that hospital orders 
the EGFR assay is whether it conducts cardiothoracic surgery. This is perhaps best 
explained by the fact that those hospitals are more likely to have thoracic surgeons who 
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may be more informed about lung cancer molecular diagnostics.  Further, there is more 
tissue available to analyze when surgery is conducted rather than a fine needle aspirate.   
Table 24 
 
 
Notes: OR of variables with p-value of less than .05 
Source: Author’s construction 
 
Across all models, participating in an NCI clinical research cooperative group 
remained a strong predictor of the institution ordering the EGFR assay.  Within jus the 
383 EGFR counties, Coop hospitals are 1.88 times more likely to order the assay 
compared to non Coop hospitals.  Within the 538 hospitals that are located within NCI 
counties, Coop hospitals are 2.15 times more likely to order the EGFR assay.  When this 
analysis is expanded to all hospitals nationally, Coop hospitals are still 2.06 times more 
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likely to order the assay.  The strength of this variable is explained by the fact that these 
hospitals are more likely to have participated in EGFR TKI clinical trials.  Therefore, 
their providers have experience ordering the assay for patients.  Or, hospitals that 
participate in NCI clinical research cooperatives may have oncologists that are more 
informed about the diagnosis and treatment of cancer patients based on the molecular 
biology of the tumor.  
Another sensitivity test distinguishes the influence of different NCI clinical 
research cooperative groups. Does participation in specific groups increase the likelihood 
the hospital ordered the EGFR assay? Error! Reference source not found. illustrates 
hat cooperative groups that offer lung cancer clinical trials (ECOG, CALGB, ACOSOG) 
were statistically significant with odds ratios between 1.70 to 2.11.  
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Table 25 
 
Notes: P-value of less than .05 have an asterisk. 
Source: Author’s construction 
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Equation 3 Results 
There are several differences between equation 2 and equation 3. The most 
significant difference is the dependent variable.  In equation 2, the dependent variable 
was a dichotomous variable (0 or 1) which measured the likelihood a hospital ordered an 
EGFR assay. The model used logistic regression analysis. The independent variables 
were regional and hospital characteristics. In equation 3, the dependent variable is the 
number of EGFR assays ordered by hospitals within a county divided by the number of 
guideline directed lung cancer cases in that county. It is calculated as a rate between 0 
and 1, with 0 indicating that no hospitals within the county ordered the assay and 1 
indicating that that the number of assays ordered by all hospitals in the county was equal 
to the number of guideline directed lung cancer cases. Because the EGFR rate is a 
continuous variable, the model will use multiple regression to analyze the independent 
variables rather than logistic regression.  Independent variables in the model are county 
level sociodemographics and county level hospital characteristics. The first thing to note 
about the model is that there are a large number of counties that have zero utilization. 
There are 2496 counties in the dataset. 383 counties had an EGFR rate greater than 0 and 
2,113 counties that had a utilization rate of 0. The large number of counties with 0 
utilization will cause the effect size of any of the regression coefficients to be small. It 
will also decrease the slope of the linear regression.  
It is worth noting that by excluding data from NCI CCs, the utilization rate 
nationally and within the counties in which the NCI CC is located, will be artificially 
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suppressed.  One test of sensitivity is to conduct a separate analysis on the 383 counties 
which had greater than 0 utilization.   
Table 26 presents the results of the multiple regression of all 2496 counties.  
Table 26 
 
Notes: P-value of less than .05 have an asterisk. 
Source: Author’s construction 
 
The distance the county is to an NCI cancer center, the number of hospitals in the county 
that participate in an NCI cooperative group, offer PET scan services, and the education 
level of the county are all statistically significant.  These coefficients can be interpreted in 
the following manner: Holding everything else constant, for every 100 miles the county is 
from a county with an NCI cancer center, the EGFR rate decreases by .001.  For every 
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hospital in the county that participates in an NCI clinical research cooperative group, the 
EGFR rate increases by .006. For every hospital in the county that offers PET scan 
services, the EGFR rate increases by .01.   And, for each percentage of the population 
that had at least a bachelor degree education, the EGFR rate increases by .103.  Education 
level of the county had the strongest influence on the EGFR rate. Although the influence 
these variables have on the EGFR rate seems so small that it is insignificant, the mean 
EGFR rate is .016. Therefore, the influence of these variables is not as insignificant as it 
may seem. 
Although the number of hospitals in the county offering cardiothoracic surgery 
was not statistically significant at .05, it was significant at a p value of .10. However, the 
direction of influence on the EGFR rate was negative.  When the number of hospitals in a 
county offering cardiothoracic surgery was analyzed independently, it had a positive 
coefficient of .007 with a p-value of .000.  Therefore, holding other variables constant, 
particularly the number of hospitals in a country that offer PET scan services and 
participate in NCI clinical research cooperatives may be masking the effect of 
cardiothoracic surgery. 
A test of sensitivity of the model was conducted by limiting analysis of the 
independent variables on the EGFR rate for the 383 counties that had a rate of greater 
than 0.  Table 27 is the multiple regressions of these 383 counties. 
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Table 27 
 
Notes: P-value of less than .05 has one asterisk. P-value of .10 has two asterisks. 
Source: Author’s construction 
 
There are three statistically significant variables: Number of hospitals in a county 
affiliated with an academic medical center, the percentage of the population within the 
county that has income over $75,000 and that self identify as Black. The number of 
hospitals in a county affiliated with an academic medical center and the percentage Black 
had the expected effects. For each additional hospital in a county affiliated with an 
academic medical center, the EGFR rate increases by .028. For each percentage point 
increase in the number of Blacks within the county, the EGFR rate decreases by .233. 
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However, for each percentage increase in the number of people reporting income over 
$75,000, had a decrease in the EGFR rate by .536.  This variable may indicating that lung 
cancer patients that live in counties which have high incomes may be more likely to 
travel outside their county to obtain care at an NCI cancer center, where the EGFR assay 
utilization rate is not captured in this model.  Alternatively, it could indicate that counties 
with high income also have lower smoking rates and lower numbers of lung cancer cases. 
However, this should be capturing in the EGFR rate. 
There are several factors that need to be noted about this model.  The R-squared is 
very low in both analyses.  The model in Table 26, all counties with acute care hospitals, 
explains .095% of the EGFR utilization rate.  Table 27, the model analyzing just the 
counties with greater than 0 utilization rate, explained approximately 3% of the model.  
This indicates that the independent variables taken together are a weak predictor of the 
EGFR utilization rate, despite having a statistically significant p values. This is not 
entirely unexpected given the lack of data from NCI CCs, the underutilization of the 
assay overall, and the fact that lung cancer incidence, which should be the most 
significant causal factor, was not statistically significant.  
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CHAPTER 5 
Conclusions and implications 
The primary objectives of this analysis were to: 
1) Identify institutional and regional factors that contributed to the adoption and 
utilization of the EGFR assay. Equation 2 of the model measured adoption of the 
EGFR assay.  It was the most successful model demonstrating that several 
hypothesized institutional characteristics were predictors of the EGFR assay.  These 
include an institution participating in an NCI clinical research cooperative group, 
offering cardiothoracic surgery, chemotherapy, and PET scan services, and affiliation 
with an academic medical center. Distance to an NCI CC was a statistically 
significant variable but the negative effect it had on likelihood the institution ordered 
the EGFR assay was not as strong as originally hypothesized. From a policy 
perspective, the most interesting finding related to this objective was the success that 
the NCI clinical research cooperative groups appear to have in diffusion knowledge 
from the NCI CC to the surrounding communities.   
2) Elucidate structural factors that may contribute to differences in access to this 
technology. This analysis clearly illustrated that institutions operating within non 
metropolitan counties are unlikely to order the EGFR assay. This finding should be 
investigated when patient level data is analyzed to determine whether patients with 
lung cancer who live in non metropolitan counties are obtaining lower quality lung 
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cancer care. Another structural factor illustrated in this analysis is that counties with a 
higher percentage of residents with college education are more likely to have an NCI 
CC located within their boundaries and are also more likely to have an institution that 
has ordered the EGFR assay, even when all other variables are factored in the model. 
These findings are consistent with many of the recent findings by the Dartmouth 
Atlas group discussed in the background and systematic review.  
3) Examine potential implications that differential rates of adoption have for poor and 
minority NSCLC patients. As mentioned in the methodological challenges, one of the 
challenges in conducting any geographic analysis of healthcare utilization is that 
patients, particularly those with serious illnesses, may cross geographic boundaries to 
seek better care. Furthermore, when the data is at the institutional and county level, it 
is not really possible to draw conclusions about patient level variables. Given that 
NCI CCs locate in metropolitan counties that have large minority populations living 
in the urban centers, without analyzing patient level data, it is impossible to prove that 
Blacks are not getting access to the EGFR assay, even if there is a strong indication in 
the clinical trials literature.  These methodological problems underscore the 
importance of conducting an analysis of patient access to lung tumor genotyping 
using the Medicare claims data. The vast majority of lung cancer patients are 
Medicare patients. Therefore, analysis of the 331,000 lung cancer patients Medicare 
claims file will provide a comprehensive analysis of quality of lung cancer care and 
variable driving access to personalized cancer care. 
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4) One of the most significant findings of this analysis was that the low utilization rate 
of the EGFR assay indicates a lack of implementation of evidenced based guidelines. 
ASCO and NCCN guidelines recommend tumors of certain lung cancer patients to be 
analyzed for an EGFR mutation. Nursing, as administrators, educators, researchers, 
policy analysts, and patient advocates play an important role in encouraging 
institutions in which they work to implement and follow evidence based clinical 
practice guidelines. The increasing complexity of cancer genomics and the pace of 
changes make it difficult for oncologists, who are already overburdened and facing a 
shortage, to be adequately and fully informed about the most recent changes in 
guidelines surrounding molecular diagnostic tests. Advanced practice and oncology 
nurses will be playing an increasingly important role in helping patients get the 
highest quality care possible.  Care that is based on evidence not anecdotal beliefs.  
By understanding the process of diffusion, nursing will be in a unique position to 
benefit patients and the profession by considering innovations in the profession that 
will solve some of the problems associated a shortage of oncologists, particularly in 
non metropolitan counties. 
It appears as though Genzyme Genetics took a traditional approach toward 
marketing the EGFR assay through physician channels.  Given the role of physicians as 
agent to the patient, this was probably the path most companies would have taken. 
However, when physicians are reluctant to change practice patterns, even in the face of 
evidence based guidelines encouraging them to do so, incrementalism may stop being the 
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most effective approach.  When patients and their advocates are educated and informed 
about innovations, it may result in faster, more disruptive innovation – particularly if 
there are strong patient advocate groups like the breast cancer advocate groups.  
There are no regulatory or reimbursement barriers that explain the slow and 
inadequate diffusion of the EGFR assay. There appears to be either a lack of knowledge 
about the innovation, among oncologists and surgeons, in addition to a lack of adherence 
to clinical practice guidelines outlining the best steps to diagnosis and treat lung cancer 
patients. This analysis suggests that only 15% of lung cancer patients are benefitting from 
this important advance in the diagnosis and treatment of lung cancer.   
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